T2 Biosystems (TTOO) 10-Q 14 Nov 22 2022 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2022	Nov. 08, 2022
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2022
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q3
Trading Symbol	TTOO
Entity Registrant Name	T2 Biosystems, Inc.
Entity Central Index Key	0001492674
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity File Number	001-36571
Entity Tax Identification Number	20-4827488
Entity Address, Address Line One	101 Hartwell Avenue
Entity Address, City or Town	Lexington
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	02421
City Area Code	781
Local Phone Number	761-4646
Entity Interactive Data Current	Yes
Title of 12(b) Security	Common Stock, par value $0.001
Security Exchange Name	NASDAQ
Entity Incorporation, State or Country Code	DE
Document Quarterly Report	true
Document Transition Report	false
Entity Common Stock, Shares Outstanding		7,319,105

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Current assets:
Cash and cash equivalents	$ 20,366,000	$ 22,245,000
Marketable securities	0	9,996,000
Accounts receivable	1,578,000	5,134,000
Inventories	4,242,000	3,909,000
Prepaid expenses and other current assets	2,690,000	3,110,000
Total current assets	28,876,000	44,394,000
Property and equipment, net	4,734,000	4,675,000
Operating lease right-of-use assets	9,058,000	9,766,000
Restricted cash	1,131,000	1,551,000
Other assets	153,000	153,000
Total assets	43,952,000	60,539,000
Current liabilities:
Accounts payable	2,063,000	2,832,000
Accrued expenses and other current liabilities	8,531,000	8,338,000
Derivative warrant liability	186,000
Deferred revenue	163,000	518,000
Total current liabilities	10,943,000	11,688,000
Notes payable	49,188,000	47,790,000
Operating lease liabilities, net of current portion	8,569,000	9,359,000
Deferred revenue, net of current portion	8,000	28,000
Derivative liability	1,792,000
Other liabilities	4,791,000	4,577,000
Commitments and contingencies (see Note 14)
Series A redeemable convertible preferred stock; $0.001 par value; 3,000 shares authorized at September 30, 2022; 3,000 shares issued and outstanding at September 30, 2022; liquidation value of $330,000; 0 shares issued and outstanding at December 31, 2021 (see Note 7)	330,000
Stockholders’ deficit
Preferred stock, $0.001 par value; 9,997,000 and 10,000,000 shares authorized at September 30, 2022 and December 31, 2021, respectively; no shares issued and outstanding at September 30, 2022 and December 31, 2021
Common stock, $0.001 par value; 400,000,000 shares authorized; 7,050,849 and 3,328,017 shares issued and outstanding at September 30, 2022 and December 31, 2021, respectively	7,000	3,000
Additional paid-in capital	492,444,000	459,314,000
Accumulated other comprehensive loss		(4,000)
Accumulated deficit	(524,120,000)	(472,216,000)
Total stockholders’ deficit	(31,669,000)	(12,903,000)
Total liabilities, Series A convertible redeemable preferred stock and stockholders’ deficit	$ 43,952,000	$ 60,539,000

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Statement Of Financial Position [Abstract]
Series A redeemable convertible preferred stock, par value (in dollars per share)	$ 0.001
Series A redeemable convertible preferred stock, shares authorized	3,000
Series A redeemable convertible preferred stock, shares issued	3,000	0
Series A redeemable convertible preferred stock, shares outstanding	3,000	0
Series A redeemable convertible preference liquidation value	$ 330,000
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	9,997,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	400,000,000	400,000,000
Common stock, shares issued	7,050,849	3,328,017
Common stock, shares outstanding	7,050,849	3,328,017

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Revenue:
Total revenue	$ 3,677	$ 7,428	$ 16,822	$ 21,078
Costs and expenses:
Research and development	6,375	6,384	21,056	16,448
Selling, general and administrative	7,017	8,536	24,071	21,983
Total costs and expenses	19,477	19,640	62,498	53,772
Loss from operations	(15,800)	(12,212)	(45,676)	(32,694)
Other income (expense):
Interest income	1	6	6	18
Interest expense	(1,560)	(1,919)	(4,556)	(5,642)
Change in fair value of derivative instrument	(117)		(1,792)	1,010
Change in fair value of derivative warrant liability	179		179
Other income (expense), net	(78)	163	(65)	211
Total other expense	(1,575)	(1,750)	(6,228)	(4,403)
Net loss	(17,375)	(13,962)	(51,904)	(37,097)
Deemed dividend on Series A redeemable convertible preferred stock	(330)		(330)
Net loss attributable to common stockholders	$ (17,705)	$ (13,962)	$ (52,234)	$ (37,097)
Net loss per share — basic	$ (2.95)	$ (4.21)	$ (12.08)	$ (11.86)
Net loss per share — diluted	$ (2.95)	$ (4.21)	$ (12.08)	$ (11.86)
Weighted-average number of common shares used in computing net loss per share — basic	6,008,819	3,317,646	4,323,452	3,127,951
Weighted-average number of common shares used in computing net loss per share — diluted	6,008,819	3,317,646	4,323,452	3,127,951
Other comprehensive loss:
Net loss	$ (17,375)	$ (13,962)	$ (51,904)	$ (37,097)
Net unrealized gain on marketable securities arising during the period			2	9
Net realized (gain) loss on marketable securities included in net loss			2	(14)
Total other comprehensive (loss) income, net of taxes			4	(5)
Comprehensive loss	(17,375)	(13,962)	(51,900)	(37,102)
Product [Member]
Revenue:
Total revenue	2,641	4,306	9,044	12,634
Costs and expenses:
Cost of product revenue	6,085	4,720	17,371	15,341
Contribution [Member]
Revenue:
Total revenue	$ 1,036	$ 3,122	$ 7,778	$ 8,444

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Series A Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($) $ in Thousands	Total	Series A Redeemable Convertible Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance at Dec. 31, 2020	$ 8,726		$ 3	$ 431,689	$ (422,975)	$ 9
Balance (in shares) at Dec. 31, 2020			2,961,579
Stock-based compensation expense	1,308			1,308
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	53			53
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)			8,253
Unrealized gain (loss) on marketable securities	7					7
Net loss	(10,660)				(10,660)
Balance at Mar. 31, 2021	(566)		$ 3	433,050	(433,635)	16
Balance (in shares) at Mar. 31, 2021			2,969,832
Balance at Dec. 31, 2020	8,726		$ 3	431,689	(422,975)	9
Balance (in shares) at Dec. 31, 2020			2,961,579
Net loss	(37,097)
Balance at Sep. 30, 2021	(2,463)		$ 3	457,602	(460,072)	4
Balance (in shares) at Sep. 30, 2021			3,319,355
Balance at Mar. 31, 2021	(566)		$ 3	433,050	(433,635)	16
Balance (in shares) at Mar. 31, 2021			2,969,832
Stock-based compensation expense	1,843			1,843
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	251			251
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)			9,253
Issuance of common stock from secondary offering, net	19,968			19,968
Issuance of common stock from secondary offering, net (in shares)			336,188
Unrealized gain (loss) on marketable securities	(12)					(12)
Net loss	(12,475)				(12,475)
Balance at Jun. 30, 2021	9,009		$ 3	455,112	(446,110)	4
Balance (in shares) at Jun. 30, 2021			3,315,273
Stock-based compensation expense	2,466			2,466
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	24			24
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)			4,082
Net loss	(13,962)				(13,962)
Balance at Sep. 30, 2021	(2,463)		$ 3	457,602	(460,072)	4
Balance (in shares) at Sep. 30, 2021			3,319,355
Balance at Dec. 31, 2021	$ (12,903)		$ 3	459,314	(472,216)	(4)
Balance (in shares) at Dec. 31, 2021	0
Balance (in shares) at Dec. 31, 2021	3,328,017		3,328,017
Stock-based compensation expense	$ 2,552			2,552
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)			40,028
Surrender of shares due to tax withholding	(231)			(231)
Surrender of shares due to tax withholding (in shares)			(10,781)
Issuance of common stock from secondary offering, net	1,433			1,433
Issuance of common stock from secondary offering, net (in shares)			70,981
Unrealized gain (loss) on marketable securities	(7)					(7)
Net loss	(16,495)				(16,495)
Balance at Mar. 31, 2022	(25,651)		$ 3	463,068	(488,711)	(11)
Balance (in shares) at Mar. 31, 2022			3,428,245
Balance at Dec. 31, 2021	$ (12,903)		$ 3	459,314	(472,216)	(4)
Balance (in shares) at Dec. 31, 2021	0
Balance (in shares) at Dec. 31, 2021	3,328,017		3,328,017
Net loss	$ (51,904)
Balance at Sep. 30, 2022	$ (31,669)		$ 7	492,444	(524,120)
Balance (in shares) at Sep. 30, 2022	3,000	3,000
Balance at Sep. 30, 2022	$ 330	$ 330
Balance (in shares) at Sep. 30, 2022	7,050,849		7,050,849
Balance at Mar. 31, 2022	$ (25,651)		$ 3	463,068	(488,711)	(11)
Balance (in shares) at Mar. 31, 2022			3,428,245
Stock-based compensation expense	1,534			1,534
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan	139			139
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)			23,386
Surrender of shares due to tax withholding	(12)			(12)
Issuance of common stock from secondary offering, net	4,494		$ 1	4,493
Issuance of common stock from secondary offering, net (in shares)			517,352
Unrealized gain (loss) on marketable securities	11					$ 11
Net loss	(18,034)				(18,034)
Balance at Jun. 30, 2022	(37,519)		$ 4	469,222	(506,745)
Balance (in shares) at Jun. 30, 2022			3,968,983
Stock-based compensation expense	1,372			1,372
Issuance of common stock from vesting of restricted stock, exercise of stock options and employee stock purchase plan (in shares)			1,365
Issuance of common stock from secondary offering, net	22,183		$ 3	22,180
Issuance of common stock from secondary offering, net (in shares)			3,080,451
Temporary equity stock issued during period (in shares)		3,000
Deemed dividend on Series A redeemable convertible preferred stock	(330)			(330)
Temporary equity, deemed dividend		$ 330
Misc adjustment to reflect rounding on reverse stock split			50
Net loss	(17,375)				(17,375)
Balance at Sep. 30, 2022	$ (31,669)		$ 7	$ 492,444	$ (524,120)
Balance (in shares) at Sep. 30, 2022	3,000	3,000
Balance at Sep. 30, 2022	$ 330	$ 330
Balance (in shares) at Sep. 30, 2022	7,050,849		7,050,849

Condensed Consolidated Statem_3

Condensed Consolidated Statement of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities
Net loss	$ (51,904)	$ (37,097)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	792	1,000
Amortization of bond premium		114
Amortization of operating lease right-of-use assets	907	982
Stock-based compensation expense	5,458	5,617
Change in fair value of derivative instrument	1,792	(1,010)
Change in fair value of derivative warrant liability	(179)
(Gain) loss on sales of marketable securities	2	(14)
(Gain) loss on issuance of Series A redeemable convertible preferred stock and derivative warrant liability	65
Impairment of property and equipment	30
Non-cash interest expense	1,613	2,803
Changes in operating assets and liabilities:
Accounts receivable	3,556	877
Prepaid expenses and other assets	356	(692)
Inventories	(815)	(1,915)
Accounts payable	(791)	523
Accrued expenses and other liabilities	61	619
Deferred revenue	(375)	9
Operating lease liabilities	(868)	(848)
Net cash used in operating activities	(40,300)	(29,032)
Cash flows from investing activities
Proceeds from maturities of marketable securities		15,251
Proceeds from sales of marketable securities	9,998
Purchases and manufacture of property and equipment	(303)	(261)
Net cash provided by investing activities	9,695	14,990
Cash flows from financing activities
Payment of employee restricted stock tax withholdings	(243)
Proceeds from issuance of shares from employee stock purchase plan and stock option exercises	139	328
Proceeds from issuance of common stock in public offerings, net of offering costs	28,110	19,968
Proceeds from issuance of Series A redeemable convertible preferred stock and derivative warrant liability	300
Net cash provided by financing activities	28,306	20,296
Net change in cash, cash equivalents and restricted cash	(2,299)	6,254
Cash, cash equivalents and restricted cash at beginning of period	23,796	17,344
Cash, cash equivalents and restricted cash at end of period	21,497	23,598
Supplemental disclosures of cash flow information
Cash paid for interest	2,916	2,815
Supplemental disclosures of noncash activities
Transfer of T2 owned instruments and components (from) to inventory	(482)	(729)
Deemed dividend on Series A redeemable convertible preferred stock	330
Right-of-use assets obtained in exchange for new operating lease liabilities	199
Purchases of property and equipment included in accounts payable and accrued expenses	$ 72	$ 80

Condensed Consolidated Statem_4

Condensed Consolidated Statement of Cash Flows (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021	Sep. 30, 2021	Dec. 31, 2020
Reconciliation of cash, cash equivalents and restricted cash at end of period
Cash and cash equivalents	$ 20,366	$ 22,245	$ 22,047
Restricted cash	1,131	1,551	1,551
Total cash, cash equivalents and restricted cash	$ 21,497	$ 23,796	$ 23,598	$ 17,344

Nature of Business

Nature of Business	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of Business	1. Nature of Business T2 Biosystems, Inc. and its subsidiary (the “Company,” “we,” or “T2”) have operations based in Lexington, Massachusetts. T2 Biosystems, Inc. was incorporated on April 27, 2006 as a Delaware corporation. The Company is an in vitro Liquidity and Going Concern At September 30, 2022, the Company had cash, cash equivalents, and restricted cash of $21.5 million, an accumulated deficit of $524.1 million and stockholders’ deficit of $31.7 million. The Company has historically experienced cash outflows from operating activities. The future success of the Company is dependent on its ability to successfully commercialize its products, obtain regulatory clearance for and successfully launch its future product candidates, obtain additional capital and ultimately attain profitable operations. Historically, the Company has funded its operations primarily through proceeds from its August 2014 initial public offering, its December 2015 public offering, its September 2016 private investment in public equity (“PIPE”) financing, its September 2017 public offering, its June 2018 public offering, its July 2019 establishment of an Equity Distribution Agreement and Equity Purchase Agreement (Note 8), its March 2021 establishment of an Equity Distribution Agreement (Note 8), private placements of redeemable convertible preferred stock as well as borrowings from debt financing arrangements. The Company is subject to a number of risks similar to other early commercial stage life science companies, including, but not limited to commercially launching the Company’s products, development and market acceptance of the Company’s product candidates, development by its competitors of new technological innovations, protection of proprietary technology, and raising additional capital. The COVID-19 pandemic has impacted and may continue to impact the Company’s operations. Although the Company did not see any material impact to accounts receivable during the three and nine month period ended September 30, 2022, the Company’s exposure may increase if its customers continue to be adversely affected by the COVID-19 pandemic, including as a result of the spread of variants of the virus. Customers may reduce their purchases of products, depending on their needs and cash flow, which could negatively impact revenue. The Company has a significant development contract with the Biomedical Advanced Research and Development Authority (“BARDA”) and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue its future product development may be impacted. The ability of the Company’s shipping carriers to deliver products to customers may be disrupted. The Company has reviewed its suppliers and quantities of key materials and believes that it has sufficient stocks and alternate sources of critical materials including personal protective equipment should the supply chains continue to be disrupted, although raw materials and plastics for the manufacturing of reagents and consumables are in high demand, and interruptions in supply are difficult to predict. Since authorization from the United States Food and Drug Administration, or FDA, was obtained to market the T2Dx Instrument, T2Candida Panel, and T2Bacteria Panel, and Emergency Use Authorization, or EUA, was issued for the T2SARS-CoV-2 Panel, the Company has incurred significant commercialization expenses related to product sales, marketing, manufacturing and distribution. If the FDA rescinds EUA, the Company would be unable to sell its T2SARS-CoV-2 tests. The Company may seek to fund its operations through public equity, private equity or debt financings, as well as other sources. However, the Company may be unable to raise additional funds or enter into such other arrangements when needed, on favorable terms, or at all. The Company’s failure to raise capital or enter into such other arrangements if and when needed would have a negative impact on the Company’s business, results of operations, financial condition and the Company’s ability to develop and commercialize T2Dx, T2Candida, T2Bacteria, T2SARS-CoV-2, and other product candidates. Pursuant to the requirements of Accounting Standards Codification (“ASC”) 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern within one year after the date that the financial statements are issued. This evaluation initially does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented as of the date the financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. The Company believes that its cash, cash equivalents, and restricted cash of $21.5 million at September 30, 2022 will not be sufficient to fund its current operating plan for at least one year from issuance of these financial statements, as certain elements of our operating plan cannot be considered probable. Absent any reductions in current operating expenses, the Company believes it will require additional financing during the first quarter of 2023. Under ASC 205-40, the future receipt of potential funding from co-development partners and other resources cannot be considered probable at this time because none of the plans are entirely within the Company’s control. The Term Loan Agreement with CRG Servicing LLC (“CRG”) (Note 6) has a minimum liquidity covenant which requires the Company to maintain a minimum cash balance of $5.0 million. There can be no assurances that the Company will continue to be in compliance with the cash covenant in future periods without additional funding. In February 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2023. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024. The Company’s stock had been trading under $1.00 since September 27, 2021. On November 5, 2021, the Company received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company was not in compliance with the requirement of Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq Global Market as a result of the closing bid price of the Company’s common stock being below per share for thirty consecutive business days (the “Bid Price Rule”). Under the Nasdaq rules, the Company had 180 days (or until May 4, 2022) to regain compliance by maintaining a minimum closing bid price of $ The Company filed an appeal and hearing request to the Nasdaq Staff’s determination to stay the delisting of the Company’s shares of common stock from Nasdaq pending the Panel’s decision. The Nasdaq Staff informed the Company that the delisting action had been stayed, pending a final written decision by the Panel, and the hearing date had been set for June 2, 2022. On June 9, 2022, the Company received a letter from the Nasdaq notifying the Company that the Nasdaq had granted the Company’s request to be transferred to The Nasdaq Capital Market, effective at the open of trading on June 13, 2022, and the Company’s request for an exception to the Bid Price Rule until November 1, 2022. On October 11, 2022, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. Following the receipt of the stockholders’ approval, the Company’s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares On July 22, 2022, the Company received a letter from the Nasdaq (the “Nasdaq Staff Deficiency Letter”) indicating that, for the last thirty-five consecutive business days, the Market Value of Listed Securities, as defined by Nasdaq (“MVLS”) had been below the $35 million minimum requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(b)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(C), the Company has been provided an initial period of 180 calendar days, or until January 18, 2023, to regain compliance. The letter states that the Nasdaq staff will provide written notification that the Company has achieved compliance with Rule 5550(b)(2) if at any time before January 18, 2023, the Company maintains its MVLS at $35 million or more for a minimum of ten consecutive business days. The Nasdaq Staff Deficiency Letter has no immediate effect on the listing or trading of the Company’s common stock. If compliance is not achieved by January 18, 2023, the Company expects that Nasdaq would provide written notification to the Company that its securities are subject to delisting. The Company will continue to monitor its MVLS and consider its available options to regain compliance with the Nasdaq minimum MVLS requirements, which may include applying for an extension of the compliance period or appealing to a Nasdaq Hearings Panel. On August 24, 2022, i n a Compliance Notice, the Nasdaq notified the Company that, from August 10, 2022 to August 23, 2022, the Company’s MVLS had been $ 35 million or greater and, accordingly, the Company had regained compliance with Rule 5550(b)(2) and that the matter was now closed. These conditions raise substantial doubt regarding the Company’s ability to continue as a going concern for a period of one year after the date that the financial statements are issued. Management's plans to alleviate the conditions that raise substantial doubt include raising additional funding, earning payments pursuant to the Company’s contract with BARDA, delaying certain research projects and capital expenditures and eliminating certain future operating expenses in order to fund operations at reduced levels for the Company to continue as a going concern for a period of 12 months from the date these unaudited condensed consolidated financial statements are issued. Management has concluded the likelihood that its plan to successfully obtain sufficient funding from one or more of these sources or adequately reduce expenditures, while reasonably possible, is less than probable. Accordingly, the Company has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for a period of at least 12 months from the date of issuance of these financial statements. The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the ordinary course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of the uncertainties described above.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	2. Summary of Significant Accounting Policies Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying interim condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders’ deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. Geographic Information The Company sells its products domestically and internationally. Total international sales were approximately $1.2 million or 32% of total revenue and $0.6 million or 9% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $3.2 million or 19% of total revenue and $1.6 million or 8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively. For the three months ended September 30, 2022, one international customer represented 12% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than 10% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than 10% of total revenue. The following table shows customers that represent greater than 10% of revenue for the period presented: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Customer A 28 % 42 % 46 % 40 % Customer B — % 14 % — % 15 % Customer C 12 % — % — % — % As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $0.9 million and $0.6 million, respectively, from customers located outside of the U.S. Net Loss Per Share The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share. Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company’s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented. Marketable Securities The Company’s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders’ deficit in accumulated other comprehensive loss (income). The Company had no marketable securities at September 30, 2022. The following table summarizes the Company’s marketable securities at December 31, 2021 (in thousands): December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 10,000 $ — $ (4 ) $ 9,996 Total $ 10,000 $ — $ (4 ) $ 9,996 The following table summarizes the maturities of the Company’s marketable securities at December 31, 2021 (in thousands): December 31, 2021 Amortized Cost Fair Value Due in less than 1 year $ 10,000 $ 9,996 Due in 1-2 years — — Total $ 10,000 $ 9,996 Derivative Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a derivative instrument. The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement. As the derivative liabilities meet the definition of a derivative, they are measured at fair value at issuance and at each reporting date in accordance with ASC 820, “ Fair Value Measurement,” Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of September 30, 2022 and December 31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established. Leases Pursuant to Topic 842, Leases In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component. Classification of Series A Redeemable Convertible Preferred Stock The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders’ deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company’s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders. Revenue Recognition The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, Revenue from Contracts with Customers • Identification of a contract with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations • Recognition of revenue as a performance obligation is satisfied The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed. Most of the Company’s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company’s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis. Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, Leases Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations. Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (“Maintenance Services”). Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional one-year Fees paid to member-owned group purchasing organizations (“GPOs”) are deducted from related product revenues. The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests. Contribution Revenue Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g overnment contract revenue is recognized as the related reimbursable expenses are incurred. The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company’s consolidated statements of operations; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance . The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. Disaggregation of Revenue The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands): Three Months Ended, September 30, Nine Months Ended, September 30, 2022 2021 2022 2021 Product revenue Instruments $ 814 $ 522 $ 2,528 $ 1,427 Consumables 1,822 3,765 6,442 11,150 Instrument rentals 5 19 74 57 Total product revenue 2,641 4,306 9,044 12,634 Contribution revenue 1,036 3,122 7,778 8,444 Total revenue $ 3,677 $ 7,428 $ 16,822 $ 21,078 Remaining Performance Obligations Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $0.1 million as of September 30, 2022. The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months. Judgments Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations. Contract Assets and Liabilities The Company recorded $0.1 million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did not record any contract assets at December 31, 2021. The Company’s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized. Contract liabilities were $0.2 million and $0.5 million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $0.4 million and related to straight-line revenue recognition associated with maintenance agreements. Cost to Obtain and Fulfill a Contract The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. At September 30, 2022, capitalized costs to fulfill contracts of less than $0.1 million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $0.1 million was included in prepaid and other current assets and less than $0.1 million was included in other non-current assets Cost of Product Revenue Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements. Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services. Selling, general and administrative expenses Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred. Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Accounting Standards Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”) In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance . This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of January 1, 2022.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Fair Value Measurements	3. Fair Value Measurements The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September 30, 2022 and December 31, 2021 (in thousands): Balance at September 30, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Derivative warrant liability $ 186 $ — $ 186 $ — Derivative liability 1,792 — — 1,792 $ 1,978 $ — $ 186 $ 1,792 Balance at December 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: US Treasury securities 9,996 9,996 — — $ 9,996 $ 9,996 $ — $ — The Company’s cash equivalents and available-for-sale marketable securities were comprised of government securities. Securities are classified as cash equivalents when the original maturities are within 90 days of the purchase dates. The Company also maintains money market accounts classified as restricted cash for $1.1 million at September 30, 2022 and $1.6 million at December 31, 2021 (Note 4). The Company estimated the fair value of the derivative warrant liability (Note 7) using the Black-Scholes Model, which uses multiple inputs including the Company’s stock price, the exercise price of the warrant, volatility of the Company’s stock price, the risk-free interest rate and the expected term of the warrant. The Company has a single compound derivative related to its Term Loan Agreement with CRG (the “Term Loan Agreement”) (Note 6), which is required to be re-measured at fair value on a quarterly basis. The fair value of the derivative at September 30, 2022 is $1.8 million and is classified as a non-current liability on the balance sheet at September 30, 2022 to match the classification of the related Term Loan Agreement (Note 6). As of December 31, 2021, the Company had no derivative liability. The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios: Probability 4% contingent interest beginning in Q1 2023 50 % The following table provides a roll-forward of the fair value of the derivative liability (in thousands): Balance at December 31, 2021 $ — Change in fair value of derivative liability 1,675 Balance at June 30, 2022 1,675 Change in fair value of derivative liability 117 Balance at September 30, 2022 $ 1,792

Restricted Cash

Restricted Cash	9 Months Ended
	Sep. 30, 2022
Restricted Cash [Abstract]
Restricted Cash	4. Restricted Cash The Company is required to maintain security deposits for its operating lease agreements for the duration of the lease agreements. At September 30, 2022, the Company had money market accounts for $1.1 million, which represented collateral as security deposits for its operating lease agreements for two facilities. At December 31, 2021, the Company had money market accounts for $1.6 million, which represented collateral as security deposits for its operating lease agreements for three facilities.

Supplemental Balance Sheet Info

Supplemental Balance Sheet Information	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Supplemental Balance Sheet Information	5. Supplemental Balance Sheet Information Inventories Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 2,195 $ 1,591 Work-in-process 1,231 953 Finished goods 816 1,365 Total inventories, net $ 4,242 $ 3,909 Property and Equipment Property and equipment consist of the following (in thousands): September 30, 2022 December 31, 2021 Office and computer equipment $ 749 $ 749 Software 783 783 Laboratory equipment 5,573 5,507 Furniture 197 197 Manufacturing equipment 1,445 1,445 Manufacturing tooling and molds 478 478 T2-owned instruments and components 7,150 6,668 Leasehold improvements 3,785 3,768 Construction in progress 774 512 20,934 20,107 Less accumulated depreciation and amortization (16,200 ) (15,432 ) Property and equipment, net $ 4,734 $ 4,675 Construction in progress is primarily comprised of equipment that has not been placed in service. T2-owned instruments and components is comprised of raw materials and work-in-process inventory that are expected to be used or used to produce T2-owned instruments, based on the Company’s business model and forecast, and completed instruments that will be used for internal research and development, clinical studies or reagent rental agreements with customers. At September 30, 2022, there was $1.0 million of raw materials or work-in-process inventory in T2-owned instruments and components compared with $1.4 million at December 31, 2021. Completed T2-owned instruments are placed in service once installation procedures are completed and are depreciated over five years. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was immaterial for the three months ended September 30, 2022 and 2021. Depreciation expense for T2-owned instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of product revenue and was $0.1 million for the nine months ended September 30, 2022 and 2021. Depreciation expense for T2-owned instruments used for internal research and development and clinical studies is recorded as a component of research and development expense. Depreciation and amortization expense of $0.3 million and $0.3 million was charged to operations for the three months ended September 30, 2022 and 2021, respectively. Depreciation and amortization expense of $0.8 million and $1.0 million was charged to operations for the nine months ended September 30, 2022 and 2021, respectively. . Accrued Expenses Accrued expenses consist of the following (in thousands): September 30, 2022 December 31, 2021 Accrued payroll and compensation $ 3,894 $ 3,687 Accrued research and development expenses 1,482 1,250 Accrued professional services 392 384 Accrued interest 1,000 974 Operating lease liabilities 1,295 1,174 Other accrued expenses 468 869 Total accrued expenses and other current liabilities $ 8,531 $ 8,338

Notes Payable

Notes Payable	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Notes Payable	6. Notes Payable Future principal payments on the notes payable are as follows (in thousands): September 30, 2022 December 31, 2021 Term Loan Agreement including PIK interest, before unamortized discount and issuance costs $ 51,597 $ 49,364 Less: unaccrued paid-in-kind interest (2,233 ) (1,287 ) Less: unamortized discount and deferred issuance costs (176 ) (287 ) Total notes payable $ 49,188 $ 47,790 The Term Loan Agreement with CRG is classified as non-current September 30, 2022 and at December 31, 2021, as the Company has sufficient cash and cash equivalents such that the minimum liquidity covenant would not be triggered. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. As amended in February 2022, the entire principal payment, together with all other outstanding obligations, under the Term Loan Agreement are due and payable upon maturity , December 30, 2023. There were no covenant violations at September 30, 2022. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024. Term Loan Agreement In December 2016, the Company entered into a Term Loan Agreement (the “Term Loan Agreement”) with CRG. The Company initially borrowed $40.0 million pursuant to the Term Loan Agreement, which has a six-year The Company may prepay all or a portion of the outstanding principal and accrued unpaid interest under the Term Loan Agreement at any time upon prior notice subject to a certain prepayment fee during the first five years of the term and no prepayment fee thereafter. As security for its obligations under the Term Loan Agreement, the Company entered into a security agreement with CRG whereby the Company granted a lien on substantially all of its assets, including intellectual property. The Term Loan Agreement also contains customary affirmative and negative covenants for a credit facility of this size and type, including a requirement to maintain a minimum cash balance of $5.0 million. In 2019, the Term Loan Agreement was amended to reduce minimum revenue targets, extend the interest-only period and extend the principal repayment. The final payment fee was increased from 8% to 10% of the principal amount outstanding upon repayment. The Company issued to CRG warrants to purchase 11,365 shares of the Company’s common stock (“New Warrants”) (Note 10) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. The Company also reduced the exercise price for the warrants previously issued to CRG to purchase an aggregate of 10,579 shares of the Company’s common stock to $77.50. All of the New Warrants are exercisable any time prior to September 9, 2029, and all of the previously issued warrants are exercisable any time prior to December 30, 2026. In January 2021, the Term Loan Agreement was amended to extend the interest-only payment period until the December 30, 2022 maturity, to extend the initial principal repayment until the December 30, 2022 maturity, and to significantly reduce the minimum product revenue target for the twenty-four month period beginning on January 1, 2020. The Company did not pay or provide any consideration in exchange for this amendment. The Company accounted for the January 2021 amendment as a modification to the Term Loan Agreement. In February 2022, the Term Loan Agreement was amended to extend the interest-only payment period through December 30, 2023, and to extend the principal repayment to December 30, 2023. The Company did not pay or provide any consideration in exchange for this amendment. As the effective borrowing rate under the amended agreement is less than the effective borrowing rate under the previous agreement, a concession is deemed to have been granted under ASC 470-60. As a concession has been granted, the agreement was accounted for as a troubled debt restructuring under ASC 470-60. The amendment did not result in a gain on restructuring as the future undiscounted cash outflows required under the amended agreement exceed the carrying value of the debt immediately prior to the amendment. In November 2022, CRG amended the Term Loan Agreement, extending the interest only period and maturity to December 30, 2024. The Term Loan Agreement includes a subjective acceleration clause whereby an event of default, including a material adverse change in the business, operations, or conditions (financial or otherwise), could result in the acceleration of the obligations under the Term Loan Agreement. Under certain circumstances, a default interest rate of an additional 4.0% per annum will apply at the election of CRG on all outstanding obligations during the occurrence and continuance of an event of default.

Series A Redeemable Convertible

Series A Redeemable Convertible Preferred Stock and Related Warrant	9 Months Ended
	Sep. 30, 2022
Temporary Equity Disclosure [Abstract]
Series A Redeemable Convertible Preferred Stock and Related Warrant	7. Series A Redeemable Convertible Preferred Stock and Related Warrant On August 15, 2022, the Company entered into a securities purchase agreement (the “Securities Purchase Agreement”), pursuant to which we entered into a private placement transaction an aggregate of 3,000 shares of Series A Redeemable Convertible Preferred Stock with a par value of $0.001 per share and a warrant to purchase up to an aggregate of 42,857 shares of common stock of the Company at an exercise price of $7.50 per share (such number of shares and exercise price adjusted for the reverse stock split described in Note 15) for an aggregate subscription amount equal to $0.3 million, before deducting estimated offering expenses payable by the Company. Pursuant to the Purchase Agreement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock with the Secretary of State of the State of Delaware designating the rights, preferences and limitations of the Series A Redeemable Convertible Preferred Stock. Series A Redeemable Convertible Preferred Stock The Series A Redeemable Convertible Preferred Stock was issued at a price of $100 per share (the Stated Value). Conversion -The Series A Redeemable Convertible Preferred Stock is convertible at the option of the holder, at any time after the date of the reverse stock split proposed by the board of directors, into that number of shares of common stock (subject to certain beneficial ownership limitations) determined by dividing the stated value of the Series A Redeemable Convertible Preferred Stock share by the conversion price then in effect, rounded down to the nearest whole share (with cash paid in lieu of any fractional shares). The initial conversion price was $7.00 per share, adjusted for the reverse stock split that was effected on October 12, 2022 (the “Conversion Price”). The Conversion Price will be (1) adjusted proportionately upon occurrence of any subsequent stock splits or stock dividends and (2) lowered to a price per share equal to that of any common stock, convertible securities or option that is subsequently issued or sold by the Company for a price per share less than the Conversion Price in effect immediately prior to such issue or sale; however, the Conversion Price cannot fall below the par value per share of the Common Stock nor exceed ten dollars ($10.00) per share, in each case, as adjusted for the reverse stock split that was effected on October 12, 2022. Redemption - Series A Redeemable Convertible Preferred Stock do not contain any mandatory redemption provisions. Beginning on the date of the reverse stock split, as proposed by the board of directors (1) the Company may redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock at a price per share equal to one hundred and five percent (105%) of the stated value and (2) each holder of Series A Preferred Stock may require the Company to redeem in cash all or any portion of the Series A Redeemable Convertible Preferred Stock held by such holder at a price per share equal to one hundred and ten percent (110%) of the stated value. In addition, if the Company’s common shares become delisted, the Series A Redeemable Convertible Preferred Stock will automatically be redeemed by the Company at a price per share equal to one hundred and ten percent (110%) of the Stated Value. At September 30, 2022, the Company determined that the Series A Redeemable Convertible Preferred Stock was redeemable and is being carried at its redemption value on the balance sheet, which is equal to its liquidation value under the terms of the certification of designation. Dividend Rights -Holders of the Series A Redeemable Convertible Preferred Stock are entitled to receive dividends on shares of Series A Redeemable Convertible Preferred Stock equal (on an as-converted to common stock basis) to and in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of the common stock. Voting Rights - The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company’s outstanding common stock (the “Proposal”) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted) Warrant In connection with the execution of the Securities Purchase Agreement, the Company issued a warrant to purchase 42,857 shares of the Company’s common stock (the “Warrant”) at an exercise price equal to $7.50 per share, subject to adjustments noted below. The Warrant will become exercisable on February 15, 2023 and has a term ending February 15, 2028. At issuance, the Company determined that the Warrant should be classified as a liability because such Warrant could require cash redemption in certain circumstances. Recognition of the warrant liability created a day one loss of $0.1 million. The Warrant is carried at fair value, with changes in fair value recognized in changes in fair value of the derivative warrant liability each reporting period. The exercise price of the Warrant and the number of shares issuable upon exercise will be adjusted proportionately upon the occurrence of any subsequent stock dividend or stock split of the Company’s common stock. In addition, if at any time the Company grants, issues or sells any c ommon s tock e quivalents or rights to purchase stock, warrants, securities or other property pro rata to holders of any class of shares of c ommon s tock (the “Purchase Rights”), then the Warrant h older will be entitled to acquire, upon the terms applicable to the Purchase Rights, the aggregate Purchase Rights which the h older could have acquired if the h older had held the number of shares of c ommon s tock acquirable upon complete exercise of the Warrant (subject to certain b eneficial o wnership limitations). Furthermore, after the issuance of the Warrant and while it is outstanding, if the Company declare s or make s any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of c ommon s tock, by way of return of capital or otherwise (a “Distribution”), the Warrant h older will be entitled to participate in that Distribution to the same extent that the h older would have participated if the h older had held the number of shares of c ommon s tock acquirable upon complete exercise of this Warrant (subject to certain b eneficial o wnership limitations). After the occurrence of a Fundamental Transaction, as defined, then, upon any subsequent exercise of the Warrant the holder will, at its option, have the right to receive for each Warrant that would have been issuable upon such exercise immediately prior to the occurrence of the Fundamental Transaction the number of shares of common stock (or its equivalent) of the successor or acquiring corporation or of the Company, if it is the surviving corporation, or such other consideration (the “Alternate Consideration”) receivable as a result of such Fundamental Transaction by a holder of the number of shares of common stock for which the Warrant is exercisable immediately prior to the Fundamental Transaction. For purposes of any such exercise, the determination of the exercise price will be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate Consideration issuable in respect of one share of common stock in such Fundamental Transaction, and the Company will apportion the exercise price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of the Alternate Consideration. If holders of common stock are given any choice as to the securities, cash or property to be received in a Fundamental Transaction, then the Warrant holder will be given the same choice as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. While any Warrant is outstanding, if the Company issues or sells, any common stock, convertible securities or options, for a consideration per share (the “New Issuance Price”) less than a price equal to the exercise price of the Warrant in effect immediately prior to such issue or sale (a “Dilutive Issuance”), then immediately after the Dilutive Issuance, the exercise price then in effect will be reduced to an amount equal to the New Issuance Price. If at the time of a Warrant’s exercise there is no effective registration statement registering, or no current prospectus available for, the resale of the Warrant Shares by the holder, then the Warrant may also be exercised, in whole or in part, at such time by means of a “cashless exercise”.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Sep. 30, 2022
Equity [Abstract]
Stockholders' Deficit	8. Stockholders’ Deficit Shares Authorized In July 2021, the Company’s shareholders approved an increase in the number of authorized shares of the Company’s common stock from 200,000,000 to 400,000,000. Equity Distribution Agreement On March 31, 2021, the Company entered into a Sales Agreement with Canaccord (“New Sales Agreement”), as agent, pursuant to which the Company may offer and sell shares of its common stock, for aggregate gross sale proceeds of up to $75.0 million from time to time from the effective date of the respective registration statement through Canaccord. Under the New Sales Agreement, upon delivery of a placement notice based on the Company’s instructions and subject to the terms and conditions of the Sales Agreement, Canaccord is able to sell the shares by methods deemed to be an “at the market” offering, subject to shelf limitations if any, in negotiated transactions at market prices prevailing at the time of sale or at prices related to such prevailing market prices, or by any other method permitted by law, including negotiated transactions, subject to the prior written consent of the Company. The Company is not obligated to make any sales of shares under the New Sales Agreement. The Company or Canaccord is able to suspend or terminate the offering of shares upon notice to the other party, subject to certain conditions. Canaccord acts as sales agent on a commercially reasonable efforts basis consistent with its normal trading and sales practices and applicable state and federal law, rules and regulations and the rules of Nasdaq. The Company agrees to pay Canaccord for its services of acting as agent an amount equal to 3% Under the New Sales Agreement, the Company sold 3,668,784 shares for net proceeds of $28.1 million during the nine months ended September 30, 2022 and 336,188 shares for net proceeds of $20.0 million during the nine months ended September 30, 2021. Under the New Sales Agreement, the Company sold 3,080,451 shares for net proceeds of $22.2 million during the three months ended September 30, 2022 and did not sell any shares during the three months ended September 30, 2021.

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Stock-Based Compensation	9. Stock-Based Compensation Stock Incentive Plans 2006 Stock Incentive Plan The Company’s 2006 Stock Option Plan (“2006 Plan”) was established for granting stock incentive awards to directors, officers, employees and consultants of the Company. Upon closing of the Company’s IPO in August 2014, the Company ceased granting stock incentive awards under the 2006 Plan. The 2006 Plan provided for the grant of incentive and non-qualified stock options and restricted stock grants as determined by the Company’s board of directors. Under the 2006 Plan, stock options were generally granted with exercise prices equal to or greater than the fair value of the common stock as determined by the board of directors, expired no later than 10 years from the date of grant, and vested over various periods not exceeding 4 years. 2014 Stock Incentive Plan The Company’s 2014 Incentive Award Plan (“2014 Plan”, and together with the 2006 Plan, the “Stock Incentive Plans”) provides for the issuance of shares of common stock in the form of stock options, awards of restricted stock, awards of restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights to directors, officers, employees and consultants of the Company. Since the establishment of the 2014 Plan, the Company has primarily granted stock options and restricted stock units. Generally, stock options are granted with exercise prices equal to or greater than the fair value of the common stock on the date of grant, expire no later than 10 years from the date of grant, and vest over various periods not exceeding 4 years. The number of shares reserved for future issuance under the 2014 Plan is the sum of (1) 16,470 shares, (2) any shares that were granted under the 2006 Plan which are forfeited, lapse unexercised or are settled in cash subsequent to the effective date of the 2014 Plan and (3) an annual increase on the first day of each calendar year beginning January 1, 2015 and ending on January 1, 2026, equal to the lesser of (A) 4% of the shares outstanding (on an as-converted basis) on the final day of the immediately preceding calendar year and (B) such smaller number of shares determined by the Company’s board of directors; provided, however, no more than 700,000 shares may be issued upon the exercise of incentive stock options. As of September 30, 2022, there were 52,676 shares available for future grant under the 2014 Plan. Inducement Award Plan The Company’s Amended and Restated Inducement Award Plan (“Inducement Plan”), which was adopted in March 2018 and most recently amended and restated in January 2020, provides for the grant of equity awards to new employees, including options, restricted stock awards, restricted stock units, performance awards, dividend equivalent awards, stock payment awards and stock appreciation rights. The aggregate number of shares of common stock which may be issued or transferred pursuant to awards under the Inducement Plan is 192,500 shares. Any awards that forfeit, expire, lapse, or are settled for cash without the delivery of shares to the holder are available for the grant of an award under the Inducement Plan. Any shares repurchased by or surrendered to the Company that are returned shall be available for the grant of an award under the Inducement Plan. The payment of dividend equivalents in cash in conjunction with any outstanding award shall not be counted against the shares available for issuance under the Inducement Plan. As of September 30, 2022, there were 84,501 shares available for future grant under the Inducement Plan. Stock Options During the nine months ended September 30, 2022 and 2021, the Company granted stock options with an aggregate fair value of $0.6 million and $1.1 million, respectively, which are being amortized into compensation expense over the vesting period of the options as the services are being provided. The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (In years) Aggregate Intrinsic Value Outstanding at December 31, 2021 197,171 $ 143.96 7.09 $ 51 Granted 33,520 21.50 Exercised — — — — Forfeited (25,608 ) 42.64 Cancelled (11,863 ) 119.60 Outstanding at September 30, 2022 193,220 $ 137.64 6.78 $ — Exercisable at September 30, 2022 127,461 $ 186.38 5.90 $ — Vested or expected to vest at September 30, 2022 182,864 $ 143.27 6.66 $ — There were no options exercised in the nine months ended September 30, 2022 and 1,566 options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September 30, 2022 and 2021 were $17.58 per share and $54.77 per share, respectively, and were calculated using the following estimated assumptions: Nine Months Ended September 30, 2022 2021 Weighted-average risk-free interest rate 2.27 % 0.92 % Expected dividend yield — % — % Expected volatility 106 % 104 % Expected terms 6.0 years 6.0 years The total fair values of options that vested during the nine months ended September 30, 2022 and 2021 were $1.4 million and $2.1 million, respectively. As of September 30, 2022, there was $2.1 million of total unrecognized compensation cost related to non-vested stock options granted under the Stock Incentive Plans and Inducement Plan. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 2.1 years as of September 30, 2022. Restricted Stock Units During the nine months ended September 30, 2022, the Company awarded restricted stock units to certain employees and directors at no cost to them. The restricted stock units, excluding any restricted stock units with market conditions, vest through the passage of time, assuming continued service. Restricted stock units are not included in issued and outstanding common stock until the underlying shares are vested and released. The fair value of the restricted stock units, at the time of the grant, is expensed on a straight line basis. The granted restricted stock units had an aggregate fair value of $3.7 million, which are being amortized into compensation expense over the vesting period of the restricted stock units as the services are being provided. The following is a summary of restricted stock unit activity under the 2014 Plan: Number of Shares Weighted-Average Grant Date Fair Value Per Share Nonvested at December 31, 2021 142,434 $ 91.77 Granted 160,575 22.79 Vested (50,352 ) 93.13 Forfeited (28,355 ) 42.40 Nonvested at September 30, 2022 224,302 $ 48.32 As of September 30, 2022, there was $8.5 million of total unrecognized compensation cost related to nonvested restricted stock units granted. Total unrecognized compensation cost will be adjusted for future changes in the estimated forfeiture rate. The Company expects to recognize that cost over a remaining weighted-average period of 1.7 years, as of September 30, 2022. Employee Stock Purchase Plan Under the 2014 Employee Stock Purchase Plan (the “2014 ESPP”) participants may purchase the Company’s common stock during semi-annual offering periods at 85% of the lower of (i) the market value per share of common stock on the first day of the offering period or (ii) the market value per share of the common stock on the purchase date. Each participant can purchase up to a maximum of $25,000 per calendar year in fair market value as calculated in accordance with applicable tax rules. The first offering period began on August 7, 2014. Stock-based compensation expense from the 2014 ESPP for the three months ended September 30, 2022 and 2021 was approximately $0.1 The 2014 ESPP, which was amended and restated effective August 6, 2020, provides for the issuance of up to 90,478 shares of the Company’s common stock to eligible employees. At September 30, 2022, there were 29,181 shares available for issuance under the 2014 ESPP. Stock-Based Compensation Expense The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of product revenue $ 64 $ 40 $ 309 $ 211 Research and development 230 269 851 707 Selling, general and administrative 1,060 2,114 4,280 4,655 Total stock-based compensation expense $ 1,354 $ 2,423 $ 5,440 $ 5,573 For the three and nine months ended September 30, 2022 and 2021, stock-based compensation expenses capitalized as part of inventory or T2Dx instruments and components were immaterial. In July 2021, a previous director of the Company resigned. In conjunction with his resignation, all of the director’s outstanding options vested in full and the exercise term was extended to the final expiration date for each respective outstanding option. Additionally, the non-vested restricted stock units granted to the director in June 2021 vested in full upon his resignation. These were accounted for as Type I equity modifications for the accelerated vesting and Type III equity modifications for the extended exercise period and resulted in an increase of $0.8 million to stock-based compensation expense for the three and nine months ended September 30, 2021. Included within selling, general and administrative above for the three and nine months ended September 30, 2021 is $0.6 million and $0.2 million related to the Type I modification and the Type III modification, respectively, from the director’s resignation.

Warrants associated with Term L

Warrants associated with Term Loan	9 Months Ended
	Sep. 30, 2022
Warrants And Rights Note Disclosure [Abstract]
Warrants Associated with Term Loan	10. Warrants associated with Term Loan In connection with the Term Loan Agreement entered into in December 2016, the Company issued to CRG warrants to purchase a total of 10,579 shares of the Company’s common stock. The warrants are exercisable any time prior to December 30, 2026 at a price of $77.50 per share, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. These warrants remain outstanding as of September 30, 2022 and December 31, 2021 . In connection with a 2019 amendment of the Term Loan Agreement, the Company issued to CRG warrants to purchase 11,365 shares of the Company’s common stock (“New Warrants”) at an exercise price of $77.50, with typical provisions for termination upon a change of control or a sale of all or substantially all of the assets of the Company. All of the New Warrants are exercisable any time prior to September 9, 2029. The New Warrants remain outstanding as of September 30, 2022 .

Net Loss Per Share

Net Loss Per Share	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Net Loss Per Share	11. Net Loss Per Share The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share. The net loss attributable to common stockholders was increased by $0.3 million to reflect the deemed dividend paid to holders of the Series A redeemable convertible preferred stock to accrete the carrying amount of that preferred stock to its redemption value. The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: Three and Nine Months Ended September 30, 2022 2021 Options to purchase common shares 193,220 186,352 Restricted stock units 224,302 134,599 Warrants to purchase common stock 64,801 21,944 Series A redeemable convertible preferred stock 3,000 — Total 485,323 342,895 Note that the net loss per share computations for all periods presented reflect the changes in the number of shares resulting from the 50 to 1

US Government Contract

US Government Contract	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
US Government Contract	12. U.S. Government Contract In September 2019, BARDA awarded the Company a milestone-based contract, with an initial value of $6.0 million, and a potential value of up to $69.0 million, if BARDA awards all contract options (the “U.S. Government Contract”). BARDA operates within the Office of the Assistant Secretary for Preparedness and Response (“ASPR”) at the U.S. Department of Health and Human Services (“HHS”). If BARDA awards and the Company completes all options, the Company’s management believes it will enable a significant expansion of the Company’s current portfolio of diagnostics for sepsis-causing pathogen and antibiotic resistance genes. In September 2020, BARDA exercised the first contract option valued at $10.5 million. In September 2021, BARDA exercised an option valued at approximately $6.4 million. In April 2021, BARDA agreed to accelerate product development by modifying the contract to advance future deliverables into the currently funded Option 1 of the BARDA contract for T2NxT, T2Biothreat, T2Resistance and T2AMR. The modification does not change the overall total potential value of the BARDA contract. On March 31, 2022, the Company announced that BARDA had exercised Option 2B under the existing multiple-year cost-share contract between BARDA and the Company and is providing an additional $4.4 million in funding to the Company. The option exercise occurred simultaneously on March 31, 2022 with a modification to the BARDA contract to make immaterial changes to, among other things, the statement of work. In September 2022, BARDA exercised Option 3 and agreed to provide an additional $3.7 million in funding for the multiple-year cost-share contract. The additional funding under Option 3 will be used to advance the U.S. clinical trials for the T2Biothreat ® ® The Company recorded contribution revenue of $1.0 million and $3.1 million for the three months ended September 30, 2022 and 2021, respectively, under the BARDA contract. The Company recorded contribution revenue of $7.8 million and $8.4 million for the nine months ended September 30, 2022 and 2021, respectively, under the BARDA contract. The Company had no outstanding accounts receivable at September 30, 2022 and accounts receivable of $1.9 million at December 31, 2021, respectively, under the BARDA contract.

Leases

Leases	9 Months Ended
	Sep. 30, 2022
Leases [Abstract]
Leases	13. Leases Operating Leases The Company leases certain office space, laboratory space and manufacturing space. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. The Company does not recognize right-of-use assets or lease liabilities for leases determined to have a term of 12 months or less. For new and amended leases, the Company has elected to account for the lease and non-lease components as a combined lease component. In May 2013, the Company entered into an operating lease for additional office, laboratory and manufacturing space in Wilmington, Massachusetts. In August 2018, the Company entered into an amendment to extend the term to December 2020 In November 2014, the Company entered into an agreement to rent additional office space in Lexington, Massachusetts. In April 2015, the Company entered into an amendment to extend the term to December 31, 2017. In connection with this agreement, the Company paid a security deposit of $50,000, which is recorded as a component of other assets in the condensed consolidated balance sheets. In May 2015, the Company entered into an amendment to expand existing manufacturing facilities in Lexington, Massachusetts. In September 2017, the Company entered into an amendment to extend the term to December 31, 2021. In June 2020, the Company vacated this office space and determined that subleasing it to a tenant was unlikely due to the impact of the COVID-19 pandemic on the local commercial real estate sub-lease market. The lease terminated on December 31, 2021. In November 2014, the Company entered into a lease for additional laboratory space in Lexington, Massachusetts. The lease term commenced in April 2015 and extended for six years. The rent expense, inclusive of the escalating rent payments, is recognized on a straight-line basis over the lease term. As an incentive to enter into the lease, the landlord paid approximately $1.4 million of the $2.2 million space build-out costs. The unamortized balance of the lease incentive as of January 1, 2019 was reclassified as a reduction to the initial recognition of the right-of-use asset related to this lease. In connection with this lease agreement, the Company paid a security deposit of $281,000, which was recorded as a component of both prepaid expenses and other current assets and other assets in the condensed consolidated balance sheets at December 31, 2019. In October 2020, the Company entered into an amendment to extend the term of the lease to October 31, 2025. In accordance with this amendment, the Company paid a replacement security deposit of $130,977, which is classified as restricted cash at September 30, 2022 and December 31, 2021 and received the initial $281,000 security deposit in return. In September 2021, the Company entered into a lease for office, research, laboratory and manufacturing space in Billerica, Massachusetts. The lease has a term of 126 months from the commencement date. At September 30, 2022, there is no effect on the operating lease right-of-use assets and lease liability accounts. The Company opened a money market account for $1.0 million, which represents collateral as a security deposit for this lease and is classified as restricted cash at September 30, 2022. Occupancy of the building has been delayed due to disagreement between the Company and the landlord as to the parties’ obligations under the lease agreement. Negotiations are on-going. The Company believes that a liability is reasonably possible but not probable. An estimate of the possible loss or range of loss cannot be made at this time. Operating leases are amortized over the lease term and included in costs and expenses in the condensed consolidated statement of operations and comprehensive loss. Variable lease costs are recognized in costs and expenses in the condensed consolidated statement of operations and comprehensive loss as incurred.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2022
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	14. Commitments and Contingencies License Agreement In 2006, the Company entered into a license agreement with a third party, pursuant to which the third party granted the Company an exclusive, worldwide, sublicenseable license under certain patent rights to make, use, import and commercialize products and processes for diagnostic, industrial and research and development purposes. The Company agreed to pay an annual license fee ranging from $5,000 to $25,000 for the royalty‑bearing license to certain patents. The Company also issued a total of 1,693 shares of common stock pursuant to the agreement in 2006 and 2007, which were recorded at fair value at the date of issuance. The Company is required to pay royalties on net sales of products and processes that are covered by patent rights licensed under the agreement at a percentage ranging between 0.5% - 3.5%, subject to reductions and offsets in certain circumstances, as well as a royalty on net sales of products that the Company sublicenses at 10 % of specified gross revenue. Royalties that became due under this agreement for the three months ended September 30 , 2022 and 2021 were immaterial . Royalties that became due under this agreement for the nine months ended September 30, 2022 and 2021 were $ 0.1 million.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2022
Subsequent Events [Abstract]
Subsequent Events	15. Subsequent Events Equity Distribution Agreement Subsequent to September 30, 2022, the Company sold 256,628 shares for net proceeds of $0.7 million under the New Sales Agreement. Reverse Stock Split On October 11, 2022, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. Following the receipt of the stockholders’ approval, the Company’s board of directions approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares Securities Purchase Agreement On October 26, 2022, the private investor in the Company’s Series A redeemable convertible preferred stock redeemed all of the Series A redeemable convertible preferred stock for an aggregate amount of $0.3 million.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Company’s financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative United States GAAP as defined in the Accounting Standards Codification (“ASC”) and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”). The Company’s condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary, T2 Biosystems Securities Corporation. All intercompany balances and transactions have been eliminated. On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares
Unaudited Interim Financial Information	Unaudited Interim Financial Information Certain information and footnote disclosures normally included in the Company’s annual financial statements have been condensed or omitted. Accordingly, these interim condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto contained in the Company’s Annual Report on Form 10-K for the year ended December 31, 2021. The accompanying interim condensed consolidated balance sheet as of September 30, 2022, the condensed consolidated statements of operations and comprehensive loss for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of Series A convertible preferred stock and stockholders’ deficit for the three and nine months ended September 30, 2022 and 2021, the condensed consolidated statements of cash flows for the nine months ended September 30, 2022 and 2021 and the related financial data and other information disclosed in these notes are unaudited. The unaudited interim financial statements have been prepared on the same basis as the audited annual financial statements, and, in the opinion of management, reflect all adjustments, consisting of normal recurring adjustments, necessary for the fair presentation of the Company’s financial position as of September 30, 2022, and the results of its operations for the three and nine months ended September 30, 2022 and 2021 and its cash flows for the nine months ended September 30, 2022 and 2021. The results for the three and nine months ended September 30, 2022 are not necessarily indicative of the results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period.
Segment Information	Segment Information Operating segments are defined as components of an enterprise about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The Company’s chief operating decision maker is the Chief Executive Officer. The Company views its operations and manages its business in one operating segment, which is the business of developing and, upon regulatory clearance, commercializing its diagnostic products aimed at lowering mortality rates, improving patient outcomes and reducing the cost of healthcare by helping medical professionals make targeted treatment decisions earlier.
Geographic Information	Geographic Information The Company sells its products domestically and internationally. Total international sales were approximately $1.2 million or 32% of total revenue and $0.6 million or 9% of total revenue for the three months ended September 30, 2022 and 2021, respectively. Total international sales were approximately $3.2 million or 19% of total revenue and $1.6 million or 8% of total revenue for the nine months ended September 30, 2022 and 2021, respectively. For the three months ended September 30, 2022, one international customer represented 12% of total revenue. For the three months ended September 30, 2021, no international customer represented greater than 10% of total revenue. For the nine months ended September 30, 2022 and 2021, no international customer represented greater than 10% of total revenue. The following table shows customers that represent greater than 10% of revenue for the period presented: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Customer A 28 % 42 % 46 % 40 % Customer B — % 14 % — % 15 % Customer C 12 % — % — % — % As of September 30, 2022 and December 31, 2021, the Company had outstanding receivables of $0.9 million and $0.6 million, respectively, from customers located outside of the U.S.
Net Loss Per Share	Net Loss Per Share The Company applies the two-class method for computing earnings per share because its Series A redeemable convertible preferred stock and the warrants issued with that preferred stock are participating securities. Under the two-class method, net income for the period is allocated between common stockholders and the participating securities according to dividends declared, if any, and participation rights in undistributed earnings. Because the Company incurred a net loss for the three and nine months ended September 30, 2022, and the holders of the participating securities do not have the contractual obligation to share in the losses of the Company on a basis that is objectively determinable, none of the net loss attributable to common stockholders was allocated to the participating securities when computing earnings per share. Basic net loss per share is calculated by dividing net loss attributable to commons stockholders by the weighted-average number of shares of common stock outstanding during the period, without consideration for common stock equivalents. Any accretion of the carrying amount of the Company’s Series A redeemable convertible preferred stock to its redemption amount is treated as a deemed dividend to the preferred stockholders and will increase the amount of the net loss attributable to common stockholders. Diluted net loss per share is calculated by adjusting the weighted-average number of shares outstanding for the dilutive effect of common stock equivalents outstanding for the period, determined using either the if-converted method (for its Series A redeemable, convertible preferred stock) or the treasury-stock method. For purposes of the diluted net loss per share calculation, stock options and unvested restricted stock, restricted stock contingently issuable upon achievement of certain market conditions, and the warrants issued with Series A redeemable convertible preferred stock are considered to be common stock equivalents but have been excluded from the calculation of diluted net loss per share, as their effect would be anti-dilutive for all periods presented. In periods in which the Company recognizes gains due to changes in the fair value of its warrant liability, the Company will further assess whether the effect of adjusting its computation of diluted net loss per share to include the potential common shares and reverse the gain associated with the warrant would result in a more diluted net loss per share, and modify the computation if necessary. The Series A redeemable convertible preferred stock was not considered a common stock equivalent because exercise of the conversion option was contingent upon occurrence of the reverse stock split, which had not yet occurred as of September 30, 2022. Therefore, basic and diluted net loss per share applicable to common stockholders was the same for all periods presented.
Marketable Securities	Marketable Securities The Company’s marketable securities consist of U.S. treasury securities, which are classified as available-for-sale and included in current assets. Available-for-sale debt securities are carried at fair value with unrealized gains and losses reported as a component of stockholders’ deficit in accumulated other comprehensive (loss) income. Realized gains and losses, if any, are included in other income (expense) in the condensed consolidated statements of operations. Available-for-sale securities are reviewed for possible impairment at least quarterly, or more frequently if circumstances arise that may indicate impairment. When the fair value of the securities declines below the amortized cost basis, impairment is indicated and it must be determined whether it is other than temporary. Impairment is considered to be other than temporary if the Company: (i) intends to sell the security, (ii) will more likely than not be forced to sell the security before recovering its cost, or (iii) does not expect to recover the security’s amortized cost basis. If the decline in fair value is considered other than temporary, the cost basis of the security is adjusted to its fair market value and the realized loss is reported in earnings. Subsequent increases or decreases in fair value are reported as a component of stockholders’ deficit in accumulated other comprehensive loss (income). The Company had no marketable securities at September 30, 2022. The following table summarizes the Company’s marketable securities at December 31, 2021 (in thousands): December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 10,000 $ — $ (4 ) $ 9,996 Total $ 10,000 $ — $ (4 ) $ 9,996 The following table summarizes the maturities of the Company’s marketable securities at December 31, 2021 (in thousands): December 31, 2021 Amortized Cost Fair Value Due in less than 1 year $ 10,000 $ 9,996 Due in 1-2 years — — Total $ 10,000 $ 9,996
Derivative Warrant Liability	Derivative Warrant Liability The Company evaluates its financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives in accordance with ASC Topic 815, “Derivatives and Hedging The Company determined that the liability for the warrant issued in conjunction with the Series A redeemable convertible preferred stock is a derivative instrument. The derivative warrant liability is classified on the condensed consolidated balance sheets as current because cash settlement of the warrant could be required by the holder within 12 months of the balance sheet date. The Company has identified a single compound derivative liability related to its Term Loan Agreement with CRG, that is classified as non-current on the condensed consolidated balance sheets to match the classification of the related Term Loan Agreement. As the derivative liabilities meet the definition of a derivative, they are measured at fair value at issuance and at each reporting date in accordance with ASC 820, “ Fair Value Measurement,”
Guarantees	Guarantees As permitted under Delaware law, the Company indemnifies its officers and directors for certain events or occurrences while each such officer or director is, or was, serving at the Company’s request in such capacity. The term of the indemnification is the officer’s or director’s lifetime. The maximum potential amount of future payments the Company could be required to make is unlimited; however, the Company has directors’ and officers’ liability insurance coverage that limits its exposure and enables the Company to recover a portion of any future amounts paid. The Company leases office, laboratory and manufacturing space under noncancelable operating leases. The Company has standard indemnification arrangements under the leases that require it to indemnify the landlords against all costs, expenses, fines, suits, claims, demands, liabilities, and actions directly resulting from any breach, violation or nonperformance of any covenant or condition of the Company’s leases. In the ordinary course of business, the Company enters into indemnification agreements with certain suppliers and business partners where the Company has certain indemnification obligations limited to the costs, expenses, fines, suits, claims, demands, liabilities and actions directly resulting from the Company’s gross negligence or willful misconduct, and in certain instances, breaches, violations or nonperformance of covenants or conditions under the agreements. As of September 30, 2022 and December 31, 2021, the Company had not experienced any material losses related to these indemnification obligations, and no material claims with respect thereto were outstanding. The Company does not expect significant claims related to these indemnification obligations and, consequently, concluded that the fair value of these obligations is negligible, and no related reserves were established.
Leases	Leases Pursuant to Topic 842, Leases In accordance with the guidance in ASC 842, components of a lease should be split into three categories: lease components (e.g. land, building, etc.), non-lease components (e.g. common area maintenance, consumables, etc.), and non-components (e.g. property taxes, insurance, etc.). Then the fixed and in-substance fixed contract consideration (including any related to non-components) must be allocated based on the respective relative fair values to the lease components and non-lease components. The Company made the policy election to not separate lease and non-lease components. Each lease component and the related non-lease components are accounted for together as a single component.
Classification of Series A Redeemable Convertible Preferred Stock	Classification of Series A Redeemable Convertible Preferred Stock The Company has applied the guidance in ASC 480-10-S99-3A, SEC Staff Announcement: Classification and Measurement of Redeemable Securities and classified the Series A redeemable convertible preferred stock as temporary equity in the mezzanine section of the balance sheet. The Series A redeemable convertible preferred stock was recorded outside of stockholders’ deficit because under the terms thereof, in the event of stockholder approval of the reverse stock split or a delisting event, which are events considered not solely within the Company’s control, the Series A redeemable convertible preferred stock becomes redeemable at the option of the holders.
Revenue Recognition	Revenue Recognition The Company generates revenue from the sale of instruments, consumable diagnostic tests, related services, reagent rental agreements and government contributions. Pursuant to ASC 606, Revenue from Contracts with Customers • Identification of a contract with a customer • Identification of the performance obligations in the contract • Determination of the transaction price • Allocation of the transaction price to the performance obligations • Recognition of revenue as a performance obligation is satisfied The amount of revenue recognized reflects the consideration the Company expects to be entitled to receive in exchange for these goods and services. Once a contract is determined to be within the scope of ASC 606 at contract inception, the Company reviews the contract to determine which performance obligations the Company must deliver and which of these performance obligations are distinct. The Company recognizes as revenues the amount of the transaction price that is allocated to the respective performance obligation when the performance obligation is satisfied or as it is satisfied. Generally, the Company's performance obligations are transferred to customers at a point in time, typically upon shipment, or over time, as services are performed. Most of the Company’s contracts with distributors in geographic regions outside the United States contain only a single performance obligation, whereas most of the Company’s contracts with direct sales customers in the United States contain multiple performance obligations. For these contracts, the Company accounts for individual performance obligations separately if they are distinct. The transaction price is allocated to the separate performance obligations on a relative standalone selling price basis. Excluded from the transaction price are sales tax and other similar taxes which are presented on a net basis. Product revenue is generated by the sale of instruments and consumable diagnostic tests predominantly through the Company’s direct sales force in the United States and distributors in geographic regions outside the United States. The Company does not offer product return or exchange rights (other than those relating to defective goods under warranty) or price protection allowances to its customers, including its distributors. Payment terms granted to distributors are the same as those granted to end-user customers and payments are not dependent upon the distributors’ receipt of payment from their end-user customers. The Company either sells instruments to customers and international distributors, or retains title and places the instrument at the customer site pursuant to a reagent rental agreement. When an instrument is purchased by a customer or international distributor, the Company recognizes revenue when the related performance obligation is satisfied (i.e. when the control of an instrument has passed to the customer; typically, at shipping point). When the instrument is placed under a reagent rental agreement, the Company’s customers generally agree to fixed term agreements, which can be extended, and incremental charges on each consumable diagnostic test purchased. Revenue from the sale of consumable diagnostic tests (under a reagent rental agreement) is generally recognized upon shipment. The transaction price from consumables purchases is allocated between the lease of the instrument (under a contingent rent methodology as provided for in ASC 842, Leases Revenue from the sale of consumable diagnostic tests (under instrument purchase agreements) is generally recognized upon shipment. Shipping and handling costs billed to customers in connection with a product sale are recorded as a component of the transaction price and allocated to product revenue in the condensed consolidated statements of operations and comprehensive loss as they are incurred by the Company in fulfilling its performance obligations. Direct sales of instruments include warranty, maintenance and technical support services typically for one year following the installation of the purchased instrument (“Maintenance Services”). Maintenance Services are separate performance obligations as they are service-based warranties and are recognized on a straight-line basis over the service delivery period. After the completion of the initial Maintenance Services period, customers have the option to renew or extend the Maintenance Services typically for additional one-year Fees paid to member-owned group purchasing organizations (“GPOs”) are deducted from related product revenues. The Company warrants that consumable diagnostic tests will be free from defects, when handled according to product specifications, for the stated life of the product. To fulfill valid warranty claims, the Company provides replacement product free of charge. Warranty expense is recognized based on the estimated defect rates of the consumable diagnostic tests. Contribution Revenue Income under the government BARDA contract is earned under a cost-sharing arrangement in which the Company is reimbursed for direct costs incurred plus allowable indirect costs. The g overnment contract revenue is recognized as the related reimbursable expenses are incurred. The cost reimbursement that is reported as revenue is presented gross of the related reimbursable expenses in the Company’s consolidated statements of operations; the related reimbursable expenses are expensed as incurred as research and development expense. The Company accounts for these contracts as a government grant which analogizes with International Accounting Standards 20 (“IAS 20”), Accounting for Government Grants and Disclosure of Government Assistance . The Company has a significant development contract with BARDA and should BARDA reduce, cancel or not grant additional milestone projects, the Company’s ability to continue future product development may be impacted. Refer to Note 12 for further details regarding the development contract with BARDA. Disaggregation of Revenue The Company disaggregates revenue from contracts with customers by type of products and services, as it best depicts how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors. The following table disaggregates our revenue by major source (in thousands): Three Months Ended, September 30, Nine Months Ended, September 30, 2022 2021 2022 2021 Product revenue Instruments $ 814 $ 522 $ 2,528 $ 1,427 Consumables 1,822 3,765 6,442 11,150 Instrument rentals 5 19 74 57 Total product revenue 2,641 4,306 9,044 12,634 Contribution revenue 1,036 3,122 7,778 8,444 Total revenue $ 3,677 $ 7,428 $ 16,822 $ 21,078 Remaining Performance Obligations Under ASC 606, the Company is required to disclose the aggregate amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations as of September 30, 2022. However, the guidance provides certain practical expedients that limit this requirement, and therefore, the Company has elected to not disclose the value of unsatisfied performance obligations for contracts with an original expected length of one year or less. The nature of the excluded unsatisfied performance obligations pursuant to the practical expedient include consumable shipments, service contracts, warranties and installation services that will be performed within one year. The amount of the transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue and that does not meet the elected practical expedient is $0.1 million as of September 30, 2022. The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months. Judgments Certain contracts with customers include promises to transfer multiple products and services to a customer. Determining whether products and services are considered distinct performance obligations that should be accounted for separately versus together may require judgment. Once the performance obligations are determined, the Company determines the transaction price, which includes estimating the amount of variable consideration, based on the most likely amount, to be included in the transaction price, if any. The Company then allocates the transaction price to each performance obligation in the contract based on a relative standalone selling price method. The corresponding revenue is recognized as the related performance obligations are satisfied as discussed in the revenue categories above. Judgment is required to determine the standalone selling price for each distinct performance obligation. The Company determines standalone selling price based on the price at which the performance obligation is sold separately. If the standalone selling price is not observable through past transactions, the Company estimates the standalone selling price taking into account available information such as a range of selling prices, market conditions and the expected costs and margin related to the performance obligations. Contract Assets and Liabilities The Company recorded $0.1 million of contract assets within other assets on the balance sheet at September 30, 2022. The contract assets represent revenue recognized for performance obligations in advance of cash receipt at the contract level based on the transaction price allocated to the respective performance obligations. The Company did not record any contract assets at December 31, 2021. The Company’s contract liabilities consist of upfront payments for research and development contracts and maintenance services on instrument sales. Contract liabilities are classified in deferred revenue as current or noncurrent based on the timing of when revenue is expected to be recognized. Contract liabilities were $0.2 million and $0.5 million at September 30, 2022 and December 31, 2021, respectively. Revenue recognized during the nine months ended September 30, 2022 relating to contract liabilities at December 31, 2021 was $0.4 million and related to straight-line revenue recognition associated with maintenance agreements. Cost to Obtain and Fulfill a Contract The Company capitalizes commission expenses paid to sales personnel that are recoverable and incremental to obtaining capital purchase agreements within the United States. These costs are classified as prepaid expenses and other current assets and other assets, based on their current or non-current nature, respectively. The Company capitalizes only those costs that are determined to be incremental and would not have occurred absent the customer contract. These capitalized costs are amortized as selling, general and administrative costs on a straight line basis over the expected period of benefit. These costs are reviewed periodically for impairment. At September 30, 2022, capitalized costs to fulfill contracts of less than $0.1 million was included in prepaid and other current assets. At December 31, 2021, capitalized costs to fulfill contracts of $0.1 million was included in prepaid and other current assets and less than $0.1 million was included in other non-current assets
Cost of Product Revenue	Cost of Product Revenue Cost of product revenue includes the cost of materials, direct labor and manufacturing overhead costs used in the manufacture of consumable diagnostic tests sold to customers, related warranty and license and royalty fees. Cost of product revenue also includes depreciation on T2-owned revenue generating T2Dx instruments that have been placed with customers under reagent rental agreements; costs of materials, direct labor and manufacturing overhead costs on the T2Dx instruments sold to customers; and other costs such as customer support costs, royalties and license fees, warranty and repair and maintenance expense on the T2Dx instruments that have been placed with customers under reagent rental agreements.
Research and Development Costs	Research and Development Costs Costs incurred in the research and development of the Company’s product candidates are expensed as incurred. Research and development expenses consist of costs incurred in performing research and development activities, including activities associated with delivering products or services associated with contribution revenue, clinical trials to evaluate the clinical utility of our product candidates, and costs associated with the enhancements of developed products. These costs include salaries and benefits, stock compensation, research related facility and overhead costs, laboratory supplies, equipment, depreciation on T2Dx instruments used for research and development activities and contract services.
Selling, General and Administrative Expenses	Selling, general and administrative expenses Selling, general and administrative expenses consist primarily of costs for our sales and marketing, finance, legal, human resources, business development and general management functions, as well as professional services, such as legal, consulting and accounting services. Other selling, general and administrative expenses include commercial support activity, facility-related costs, fees and expenses associated with obtaining and maintaining patents, clinical and economic studies and publications, marketing expenses, and travel expenses. We expense the majority of selling, general and administrative expenses as incurred.
Recent Accounting Standards	Recent Accounting Standards From time to time, new accounting pronouncements are issued by the FASB or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the Company believes that the impact of recently issued standards that are not yet effective will not have a material impact on its financial position or results of operations upon adoption. Accounting Standards Adopted In August 2020, the FASB issued ASU No. 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40)—Accounting for Convertible Instruments and Contracts in an Entity's Own Equity In May 2021, the FASB issued ASU No. 2021-04, Earnings Per Share (Topic 260), Debt-Modifications and Extinguishments (Subtopic 470-50), Compensation-Stock Compensation (Topic 718), and Derivatives and Hedging-Contracts in Entity’s Own Equity (Subtopic 815-40) Issuer’s Accounting for Certain Modifications or Exchanges of Freestanding Equity-Classified Written Call Options (“ASU 2021-04”) In November 2021, the FASB issued ASU 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance . This ASU requires certain disclosures when companies (a) have received government assistance and (b) use a grant or contribution accounting model by analogy to other accounting guidance. A company that has received government assistance must provide disclosures related to the nature of the transaction, accounting policies used to account for the transaction, and the amounts and line items on the financial statements that are affected by the transaction. This ASU is effective for fiscal years beginning after December 15, 2021, with early adoption permitted, and can be applied either prospectively or retrospectively. The Company adopted this standard as of January 1, 2022.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2022
Accounting Policies [Abstract]
Schedule of Customers Represent Greater Than 10% Of Revenue	The following table shows customers that represent greater than 10% of revenue for the period presented: Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Customer A 28 % 42 % 46 % 40 % Customer B — % 14 % — % 15 % Customer C 12 % — % — % — %
Summary of Marketable Securities	The Company had no marketable securities at September 30, 2022. The following table summarizes the Company’s marketable securities at December 31, 2021 (in thousands): December 31, 2021 Amortized Cost Gross Unrealized Gains Gross Unrealized Losses Fair Value U.S. treasury securities $ 10,000 $ — $ (4 ) $ 9,996 Total $ 10,000 $ — $ (4 ) $ 9,996
Summary of Maturities of Marketable Securities	The following table summarizes the maturities of the Company’s marketable securities at December 31, 2021 (in thousands): December 31, 2021 Amortized Cost Fair Value Due in less than 1 year $ 10,000 $ 9,996 Due in 1-2 years — — Total $ 10,000 $ 9,996
Disaggregation of Revenue by Major Source	The following table disaggregates our revenue by major source (in thousands): Three Months Ended, September 30, Nine Months Ended, September 30, 2022 2021 2022 2021 Product revenue Instruments $ 814 $ 522 $ 2,528 $ 1,427 Consumables 1,822 3,765 6,442 11,150 Instrument rentals 5 19 74 57 Total product revenue 2,641 4,306 9,044 12,634 Contribution revenue 1,036 3,122 7,778 8,444 Total revenue $ 3,677 $ 7,428 $ 16,822 $ 21,078

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2022
Fair Value Disclosures [Abstract]
Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis	The Company measures the following financial assets at fair value on a recurring basis. There were no transfers between levels of the fair value hierarchy during any of the periods presented. The following tables set forth the Company’s financial assets and liabilities carried at fair value categorized using the lowest level of input applicable to each financial instrument as of September 30, 2022 and December 31, 2021 (in thousands): Balance at September 30, 2022 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Liabilities: Derivative warrant liability $ 186 $ — $ 186 $ — Derivative liability 1,792 — — 1,792 $ 1,978 $ — $ 186 $ 1,792 Balance at December 31, 2021 Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets: US Treasury securities 9,996 9,996 — — $ 9,996 $ 9,996 $ — $ —
Summary of Contingent Interest Payments	The estimated fair value of the derivative at September 30, 2022 was determined using a probability-weighted discounted cash flow model that includes contingent interest payments under the following scenarios: Probability 4% contingent interest beginning in Q1 2023 50 %
Roll-Forward of Fair Value of Derivative Liability	The following table provides a roll-forward of the fair value of the derivative liability (in thousands): Balance at December 31, 2021 $ — Change in fair value of derivative liability 1,675 Balance at June 30, 2022 1,675 Change in fair value of derivative liability 117 Balance at September 30, 2022 $ 1,792

Supplemental Balance Sheet In_2

Supplemental Balance Sheet Information (Tables)	9 Months Ended
	Sep. 30, 2022
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Schedule of Inventory	Inventories are stated at the lower of cost or net realizable value on a first-in, first-out basis and are comprised of the following (in thousands): September 30, 2022 December 31, 2021 Raw materials $ 2,195 $ 1,591 Work-in-process 1,231 953 Finished goods 816 1,365 Total inventories, net $ 4,242 $ 3,909
Schedule of Property and Equipment	Property and equipment consist of the following (in thousands): September 30, 2022 December 31, 2021 Office and computer equipment $ 749 $ 749 Software 783 783 Laboratory equipment 5,573 5,507 Furniture 197 197 Manufacturing equipment 1,445 1,445 Manufacturing tooling and molds 478 478 T2-owned instruments and components 7,150 6,668 Leasehold improvements 3,785 3,768 Construction in progress 774 512 20,934 20,107 Less accumulated depreciation and amortization (16,200 ) (15,432 ) Property and equipment, net $ 4,734 $ 4,675
Components of Accrued Expenses	Accrued expenses consist of the following (in thousands): September 30, 2022 December 31, 2021 Accrued payroll and compensation $ 3,894 $ 3,687 Accrued research and development expenses 1,482 1,250 Accrued professional services 392 384 Accrued interest 1,000 974 Operating lease liabilities 1,295 1,174 Other accrued expenses 468 869 Total accrued expenses and other current liabilities $ 8,531 $ 8,338

Notes Payable (Tables)

Notes Payable (Tables)	9 Months Ended
	Sep. 30, 2022
Debt Disclosure [Abstract]
Schedule of Debt	Future principal payments on the notes payable are as follows (in thousands): September 30, 2022 December 31, 2021 Term Loan Agreement including PIK interest, before unamortized discount and issuance costs $ 51,597 $ 49,364 Less: unaccrued paid-in-kind interest (2,233 ) (1,287 ) Less: unamortized discount and deferred issuance costs (176 ) (287 ) Total notes payable $ 49,188 $ 47,790

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2022
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Summary of Stock Option Activity	The following is a summary of option activity under the Stock Incentive Plans and Inducement Plan (in thousands, except share and per share amounts): Number of Shares Weighted-Average Exercise Price Per Share Weighted-Average Remaining Contractual Term (In years) Aggregate Intrinsic Value Outstanding at December 31, 2021 197,171 $ 143.96 7.09 $ 51 Granted 33,520 21.50 Exercised — — — — Forfeited (25,608 ) 42.64 Cancelled (11,863 ) 119.60 Outstanding at September 30, 2022 193,220 $ 137.64 6.78 $ — Exercisable at September 30, 2022 127,461 $ 186.38 5.90 $ — Vested or expected to vest at September 30, 2022 182,864 $ 143.27 6.66 $ —
Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted	There were no options exercised in the nine months ended September 30, 2022 and 1,566 options exercised in the nine months ended September 30, 2021. The weighted-average grant date fair values of stock options granted in the nine month periods ended September 30, 2022 and 2021 were $17.58 per share and $54.77 per share, respectively, and were calculated using the following estimated assumptions: Nine Months Ended September 30, 2022 2021 Weighted-average risk-free interest rate 2.27 % 0.92 % Expected dividend yield — % — % Expected volatility 106 % 104 % Expected terms 6.0 years 6.0 years
Schedule of Nonvested Restricted Stock Units Activity	The following is a summary of restricted stock unit activity under the 2014 Plan: Number of Shares Weighted-Average Grant Date Fair Value Per Share Nonvested at December 31, 2021 142,434 $ 91.77 Granted 160,575 22.79 Vested (50,352 ) 93.13 Forfeited (28,355 ) 42.40 Nonvested at September 30, 2022 224,302 $ 48.32
Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations	The following table summarizes the stock-based compensation expense resulting from awards granted under Stock Incentive Plans, the Inducement Plan and the 2014 ESPP, that was recorded in the Company’s results of operations for the periods presented (in thousands): Three Months Ended September 30, Nine Months Ended September 30, 2022 2021 2022 2021 Cost of product revenue $ 64 $ 40 $ 309 $ 211 Research and development 230 269 851 707 Selling, general and administrative 1,060 2,114 4,280 4,655 Total stock-based compensation expense $ 1,354 $ 2,423 $ 5,440 $ 5,573

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	9 Months Ended
	Sep. 30, 2022
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The following shares were excluded from the calculation of diluted net loss per share applicable to common stockholders, prior to the application of the treasury stock or if-converted methods, because their effect would have been anti-dilutive for the periods presented: Three and Nine Months Ended September 30, 2022 2021 Options to purchase common shares 193,220 186,352 Restricted stock units 224,302 134,599 Warrants to purchase common stock 64,801 21,944 Series A redeemable convertible preferred stock 3,000 — Total 485,323 342,895

Nature of Business - Additional

Nature of Business - Additional Information (Detail)

1 Months Ended

9 Months Ended

Nov. 14, 2022

Oct. 12, 2022

Oct. 11, 2022

Feb. 28, 2022

Sep. 30, 2022 USD ($) $ / shares

Aug. 24, 2022 USD ($)

Jul. 22, 2022 USD ($)

Jun. 30, 2022 USD ($)

Mar. 31, 2022 USD ($)

Dec. 31, 2021 USD ($)

Nov. 05, 2021 $ / shares

Sep. 30, 2021 USD ($)

Jun. 30, 2021 USD ($)

Mar. 31, 2021 USD ($)

Dec. 31, 2020 USD ($)

Nature Of Business [Line Items]

Cash, cash equivalents, and restricted cash

$ 21,500,000

Accumulated deficit

524,120,000

$ 472,216,000

Stockholders' deficit

$ 31,669,000

$ 37,519,000

$ 25,651,000

$ 12,903,000

$ 2,463,000

$ (9,009,000)

$ 566,000

$ (8,726,000)

Bid price of common stock | $ / shares

$ 1

Stock split, conversion ratio

0.02

Reverse stock split description

the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.

Minimum market value of listed securities

$ 35,000,000

$ 35,000,000

Maximum [Member]

Nature Of Business [Line Items]

Stock trading price | $ / shares

$ 1

Minimum [Member]

Nature Of Business [Line Items]

Regain compliance by increasing the stock price | $ / shares

$ 1

Term Loan Agreement [Member] | CRG [Member]

Nature Of Business [Line Items]

Minimum cash balance

$ 5,000,000

Debt maturity date

Dec. 30, 2023

Subsequent Event [Member]

Nature Of Business [Line Items]

Stock split, conversion ratio

0.02

0.02

Reverse stock split description

On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise

On October 11, 2022, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. Following the receipt of the stockholders’ approval, the Company’s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule.

Subsequent Event [Member] | Term Loan Agreement [Member] | CRG [Member]

Nature Of Business [Line Items]

Debt maturity date

Dec. 30, 2024

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Detail)			3 Months Ended		9 Months Ended
	Oct. 12, 2022	Oct. 11, 2022	Sep. 30, 2022 USD ($)	Sep. 30, 2021 USD ($)	Sep. 30, 2022 USD ($) Segment	Sep. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)
Product Information [Line Items]
Stock split, conversion ratio					0.02
Reverse stock split description					the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.
Number of operating segments | Segment					1
Total revenue			$ 3,677,000	$ 7,428,000	$ 16,822,000	$ 21,078,000
Outstanding receivable			1,578,000		1,578,000		$ 5,134,000
Marketable securities			0		$ 0		9,996,000
Remaining performance obligation, expected timing of satisfaction					The Company expects to recognize 86% of this amount as revenue within one year and the remainder within fifteen months.
Contract assets							0
Contract liabilities			$ 200,000		$ 200,000		500,000
Revenue recognized relating to contract liabilities					$ 400,000
Accounting Standards Update 2020-06 [Member]
Product Information [Line Items]
Change in accounting principle, accounting standards update, adopted			true		true
Change in accounting principle, accounting standards update, adoption date			Jan. 01, 2022		Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect			true		true
Accounting Standards Update 2021-04 [Member]
Product Information [Line Items]
Change in accounting principle, accounting standards update, adopted			true		true
Change in accounting principle, accounting standards update, adoption date			Jan. 01, 2022		Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect			true		true
Accounting Standards Update 2021-10 [Member]
Product Information [Line Items]
Change in accounting principle, accounting standards update, adopted			true		true
Change in accounting principle, accounting standards update, adoption date			Jan. 01, 2022		Jan. 01, 2022
Change in accounting principle, accounting standards update, immaterial effect			true		true
Other Non-Current Assets [Member]
Product Information [Line Items]
Contract assets			$ 100,000		$ 100,000
Prepaid and Other Current Assets [Member]
Product Information [Line Items]
Costs to obtain or fulfill contract capitalized							100,000
T2 Dx [Member]
Product Information [Line Items]
Maintenance Services period (in years)					1 year
Additional period for Maintenance Service option (in years)					1 year
Maximum [Member]
Product Information [Line Items]
Original expected period of contracts for which value of unsatisfied performance obligations not to be disclosed					1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period			15 months		15 months
Maximum [Member] | Other Non-Current Assets [Member]
Product Information [Line Items]
Costs to obtain or fulfill contract capitalized							100,000
Maximum [Member] | Prepaid and Other Current Assets [Member]
Product Information [Line Items]
Costs to obtain or fulfill contract capitalized			$ 100,000		$ 100,000
Non-US [Member]
Product Information [Line Items]
Total revenue			1,200,000	$ 600,000	3,200,000	$ 1,600,000
Outstanding receivable			$ 900,000		$ 900,000		$ 600,000
Revenue [Member] | Geographic Concentration Risk [Member] | Non-US [Member]
Product Information [Line Items]
Total revenue (as a percent)			32%	9%	19%	8%
Revenue [Member] | Geographic Concentration Risk [Member] | Non-US [Member] | Maximum [Member]
Product Information [Line Items]
Total revenue (as a percent)			12%	10%	10%	10%
Subsequent Event [Member]
Product Information [Line Items]
Stock split, conversion ratio	0.02	0.02
Reverse stock split description	On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise	On October 11, 2022, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. Following the receipt of the stockholders’ approval, the Company’s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule.

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Customers Represent Greater Than 10% Of Revenue (Detail) - Customer Concentration Risk [Member] - Revenue [Member]	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Customer A [Member]
Product Information [Line Items]
Total revenue (as a percent)	28%	42%	46%	40%
Customer B [Member]
Product Information [Line Items]
Total revenue (as a percent)		14%		15%
Customer C [Member]
Product Information [Line Items]
Total revenue (as a percent)	12%

Summary of Significant Accoun_6

Summary of Significant Accounting Policies - Summary of Marketable Securities (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Marketable Securities [Line Items]
Amortized Cost	$ 10,000
Gross Unrealized Losses	(4)
Fair Value	9,996
U.S. Treasury Securities [Member]
Marketable Securities [Line Items]
Amortized Cost	10,000
Gross Unrealized Losses	(4)
Fair Value	$ 9,996

Summary of Significant Accoun_7

Summary of Significant Accounting Policies - Summary of Maturities of Marketable Securities (Detail) $ in Thousands	Dec. 31, 2021 USD ($)
Accounting Policies [Abstract]
Marketable Securities, Amortized Cost, Due in less than 1 year	$ 10,000
Amortized Cost	10,000
Marketable Securities, Fair Value, Due in less than 1 year	9,996
Marketable Securities, Fair Value	$ 9,996

Summary of Significant Accoun_8

Summary of Significant Accounting Policies - Disaggregation of Revenue by Major Resource (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Disaggregation Of Revenue [Line Items]
Total revenue	$ 3,677	$ 7,428	$ 16,822	$ 21,078
Product Instruments [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	814	522	2,528	1,427
Product Consumables [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	1,822	3,765	6,442	11,150
Instrument Rentals [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	5	19	74	57
Total Product Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	2,641	4,306	9,044	12,634
Contribution Revenue [Member]
Disaggregation Of Revenue [Line Items]
Total revenue	$ 1,036	$ 3,122	$ 7,778	$ 8,444

Summary of Significant Accoun_9

Summary of Significant Accounting Policies - Additional Information 1 (Detail) - Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-10-01 $ in Millions	Sep. 30, 2022 USD ($)
Product Information [Line Items]
Transaction price that is allocated to unsatisfied or partially satisfied performance obligations, that has not yet been recognized as revenue	$ 0.1
Percentage of revenue recognition	86%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period	1 year

Fair Value Measurements - Sched

Fair Value Measurements - Schedule of Financial Assets and Liabilities at Fair value on a Recurring Basis (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Jun. 30, 2022	Dec. 31, 2021
Assets:
Assets, fair value			$ 9,996
Liabilities:
Derivative warrant liability	$ 186
Derivative liability	1,792	$ 1,675
Estimate of Fair Value Measurement [Member] | Recurring [Member]
Assets:
Total assets			9,996
Liabilities:
Derivative warrant liability	186
Derivative liability	1,792
Total liabilities	1,978
Estimate of Fair Value Measurement [Member] | Recurring [Member] | U.S. Treasury Securities [Member]
Assets:
Assets, fair value			9,996
Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]
Assets:
Total assets			9,996
Level 1 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member] | U.S. Treasury Securities [Member]
Assets:
Assets, fair value			$ 9,996
Level 2 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]
Liabilities:
Derivative warrant liability	186
Total liabilities	186
Level 3 [Member] | Estimate of Fair Value Measurement [Member] | Recurring [Member]
Liabilities:
Derivative liability	1,792
Total liabilities	$ 1,792

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail) - USD ($)	Sep. 30, 2022	Dec. 31, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	$ 1,792,000
CRG [Member] | Term Loan Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Derivative liability	1,800,000	$ 0
Money Market Accounts [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Restricted cash	$ 1,100,000	$ 1,600,000

Fair Value Measurements - Summa

Fair Value Measurements - Summary of Contingent Interest Payments (Detail)	9 Months Ended
	Sep. 30, 2022
Contingent Interest Beginning in Q1 2023 [Member] | Measurement Input, Discount Rate [Member] | Term Loan Agreement [Member] | CRG [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
4% contingent interest beginning in Q1 2023, probability	50%

Fair Value Measurements - Sum_2

Fair Value Measurements - Summary of Contingent Interest Payments (Parenthetical) (Detail)	9 Months Ended
	Sep. 30, 2022
CRG [Member] | Term Loan Agreement [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent payment of interest rate	4%

Fair Value Measurements - Roll-

Fair Value Measurements - Roll-Forward of Fair Value of Derivative Liability (Detail) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended	9 Months Ended
	Sep. 30, 2022	Jun. 30, 2022	Sep. 30, 2022	Sep. 30, 2021
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Beginning balance	$ 1,675
Change in fair value of derivative instrument	(117)		$ (1,792)	$ 1,010
Ending balance	1,792	$ 1,675	$ 1,792
Probability Weighted Discounted Cash Flow Model
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Change in fair value of derivative instrument	$ 117	$ 1,675

Restricted Cash - Additional In

Restricted Cash - Additional Information (Detail) - Money Market Accounts [Member] $ in Millions	9 Months Ended	12 Months Ended
	Sep. 30, 2022 USD ($) Facility	Dec. 31, 2021 USD ($) Facility
Restricted Cash And Cash Equivalents Items [Line Items]
Security deposits | $	$ 1.1	$ 1.6
Number of facilities | Facility	2	3

Supplemental Balance Sheet In_3

Supplemental Balance Sheet Information - Schedule of Inventory (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Inventory Net [Abstract]
Raw materials	$ 2,195	$ 1,591
Work-in-process	1,231	953
Finished goods	816	1,365
Total inventories, net	$ 4,242	$ 3,909

Supplemental Balance Sheet In_4

Supplemental Balance Sheet Information - Schedule of Property and Equipment (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 20,934	$ 20,107
Less accumulated depreciation and amortization	(16,200)	(15,432)
Property and equipment, net	4,734	4,675
Office and Computer Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	749	749
Software [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	783	783
Laboratory Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	5,573	5,507
Furniture [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	197	197
Manufacturing Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,445	1,445
Manufacturing Tooling and Molds [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	478	478
T2-Owned Instruments and Components [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	7,150	6,668
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	3,785	3,768
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 774	$ 512

Supplemental Balance Sheet In_5

Supplemental Balance Sheet Information - Additional Information (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Supplemental Balance Sheet Information [Line Items]
Raw materials and work-in-process inventory	$ 1,000		$ 1,000		$ 1,400
Depreciation and amortization	$ 300	$ 300	$ 792	$ 1,000
T2 Owned Instruments in Service [Member]
Supplemental Balance Sheet Information [Line Items]
Estimated useful lives (in years)			5 years
T2 Owned Instruments in Service [Member] | Product [Member]
Supplemental Balance Sheet Information [Line Items]
Depreciation expense recorded as a component of cost of product revenue			$ 100	$ 100

Supplemental Balance Sheet In_6

Supplemental Balance Sheet Information - Components of Accrued Expenses (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Accrued Liabilities Current [Abstract]
Accrued payroll and compensation	$ 3,894	$ 3,687
Accrued research and development expenses	1,482	1,250
Accrued professional services	392	384
Accrued interest	1,000	974
Operating lease liabilities	1,295	1,174
Other accrued expenses	468	869
Total accrued expenses and other current liabilities	$ 8,531	$ 8,338

Notes Payable - Schedule of Deb

Notes Payable - Schedule of Debt (Detail) - USD ($) $ in Thousands	Sep. 30, 2022	Dec. 31, 2021
Debt Disclosure [Abstract]
Term Loan Agreement including PIK interest, before unamortized discount and issuance costs	$ 51,597	$ 49,364
Less: unaccrued paid-in-kind interest	(2,233)	(1,287)
Less: unamortized discount and deferred issuance costs	(176)	(287)
Total notes payable	$ 49,188	$ 47,790

Notes Payable - Term Loan Agree

Notes Payable - Term Loan Agreement - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		1 Months Ended		9 Months Ended
	Nov. 14, 2022	Feb. 28, 2022	Dec. 31, 2016	Sep. 30, 2022	Dec. 31, 2019
Common Stock [Member]
Debt Instrument [Line Items]
Number of shares issuable for warrants outstanding (in shares)			10,579		11,365
Exercise price of warrants			$ 77.50		$ 77.50
CRG [Member] | Term Loan Agreement [Member]
Debt Instrument [Line Items]
Debt maturity date		Dec. 30, 2023
Proceeds from issuance of long-term debt			$ 40
Debt term (in years)			6 years
Debt instrument, term of interest-only payments (in years)			4 years
Final fee as a percentage of the principal outstanding (as a percent)			8%	10%	10%
Annual fixed rate (as a percent)			11.50%
Deferred interest rate (as a percent)			3.50%
Debt instrument, prepayment fee term (in years)			5 years
Minimum cash balance				$ 5
Additional interest rate, event of default (as a percent)				4%
CRG [Member] | Term Loan Agreement [Member] | Subsequent Event [Member]
Debt Instrument [Line Items]
Debt maturity date	Dec. 30, 2024

Series A Redeemable Convertib_2

Series A Redeemable Convertible Preferred Stock and Related Warrant - Additional Information (Detail) - USD ($) $ / shares in Units, $ in Millions		9 Months Ended
	Aug. 15, 2022	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2019	Dec. 31, 2016
Temporary Equity [Line Items]
Series A redeemable convertible preferred stock, shares issued		3,000	0
Series A redeemable convertible preferred stock, par value (in dollars per share)		$ 0.001
Purchase Agreement [Member]
Temporary Equity [Line Items]
Warrants exercisable date	Feb. 15, 2023
Warrants maturity term	Feb. 15, 2028
Warrant liability	$ 0.1
Common Stock [Member]
Temporary Equity [Line Items]
Number of shares issuable for warrants outstanding (in shares)				11,365	10,579
Exercise price of warrants				$ 77.50	$ 77.50
Common Stock [Member] | Purchase Agreement [Member]
Temporary Equity [Line Items]
Number of shares issuable for warrants outstanding (in shares)	42,857
Exercise price of warrants	$ 7.50
Aggregate subscription amount	$ 0.3
Series A Redeemable Convertible Preferred Stock [Member] | Purchase Agreement [Member]
Temporary Equity [Line Items]
Series A redeemable convertible preferred stock, shares issued	3,000
Series A redeemable convertible preferred stock, par value (in dollars per share)	$ 0.001
Temporary equity issued, price per share	100
Conversion price of preferred shares	$ 7
Conversion date of preferred shares	Oct. 12, 2022
Preferred stock price percentage on stated value	105%
Preferred stock price percentage on stated value, held by holders of preferred stock	110%
Preferred stock price percentage on stated value, automatically redeemable upon delisting of common shares	110%
Voting rights		The Series A Redeemable Convertible Preferred Stock will have no voting rights other than the right to vote on certain matters. Each share of Series A Redeemable Convertible Preferred entitles the holder to 1,000,000 votes on a proposal to approve a reverse stock split of the Company’s outstanding common stock (the “Proposal”) and any proposal to adjourn any meeting of stockholders called for the purpose of voting on the Proposal; provided, however, that such shares of Series A Redeemable Convertible Preferred Stock shall be voted in the same proportion as the shares of common stock (excluding any shares of common stock that are not voted)
Series A Redeemable Convertible Preferred Stock [Member] | Purchase Agreement [Member] | Maximum [Member]
Temporary Equity [Line Items]
Conversion price of preferred shares	$ 10

Stockholders' Deficit - Additio

Stockholders' Deficit - Additional Information (Detail) - USD ($)			3 Months Ended		9 Months Ended
	Mar. 31, 2021	Jul. 30, 2019	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Jul. 01, 2021	Jun. 30, 2021
Class Of Stock [Line Items]
Common stock, shares authorized			400,000,000		400,000,000		400,000,000	400,000,000	200,000,000
New Sales Agreement [Member] | Canaccord [Member]
Class Of Stock [Line Items]
Aggregate gross sales amount of common stock	$ 75,000,000
Percentage of agent service fee		3%
Number of shares issued/sold			3,080,451	0	3,668,784	336,188
Proceeds from issuance of common stock			$ 22,200,000		$ 28,100,000	$ 20,000,000
Original Sales Agreement | Canaccord [Member]
Class Of Stock [Line Items]
Percentage of agent service fee		3%

Stock-Based Compensation - Addi

Stock-Based Compensation - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Aug. 06, 2020	Mar. 31, 2018
Share-Based Compensation
Fair value of vested stock options			$ 1,400,000	$ 2,100,000
Stock-based compensation expense	$ 1,354,000	$ 2,423,000	5,440,000	5,573,000
Selling, general and administrative	$ 7,017,000	8,536,000	$ 24,071,000	21,983,000
Director [Member] | Type I Modification [Member]
Share-Based Compensation
Stock-based compensation expense		800,000		800,000
Selling, general and administrative		600,000		600,000
Director [Member] | Type III Modification [Member]
Share-Based Compensation
Stock-based compensation expense		800,000		800,000
Selling, general and administrative		200,000		200,000
Employee Stock Purchase Plan [Member]
Share-Based Compensation
Shares available for grant	29,181		29,181
Shares available for authorization					90,478
Percentage of full share price paid in purchase of common stock			85%
Maximum amount of annual employee common stock purchases			$ 25,000
Stock-based compensation expense	$ 100,000	$ 100,000	$ 300,000	300,000
Restricted Stock Units [Member]
Share-Based Compensation
Weighted-average period			1 year 8 months 12 days
Unrecognized compensation cost related to unvested stock options	$ 8,500,000		$ 8,500,000
2014 Stock Option Plan [Member] | Stock Options [Member]
Share-Based Compensation
Shares available for future issuance under stock incentive plan	16,470		16,470
Percentage of common shares outstanding	4%		4%
Shares available for grant	52,676		52,676
Inducement Award Plan [Member]
Share-Based Compensation
Shares available for grant	84,501		84,501
Shares available for authorization						192,500
2006 and 2014 Stock Option Plans [Member] | Stock Options [Member]
Share-Based Compensation
Aggregate fair value of options granted			$ 600,000	$ 1,100,000
Unrecognized compensation cost related to non-vested stock options	$ 2,100,000		$ 2,100,000
Weighted-average period			2 years 1 month 6 days
2006 and 2014 Stock Option Plans and Inducement Plan [Member] | Stock Options [Member]
Share-Based Compensation
Issuance of common stock from exercise of stock options (in shares)			0	1,566
Weighted average fair value of options granted			$ 17.58	$ 54.77
2006 and 2014 Stock Option Plans and Inducement Plan [Member] | Restricted Stock Units [Member]
Share-Based Compensation
Aggregate fair value of restricted stock units granted			$ 3,700,000
Maximum [Member] | 2006 Stock Option Plan [Member] | Stock Options [Member]
Share-Based Compensation
Expiration period			10 years
Vesting period			4 years
Maximum [Member] | 2014 Stock Option Plan [Member] | Stock Options [Member]
Share-Based Compensation
Expiration period			10 years
Vesting period			4 years
Issuance of common stock from exercise of stock options (in shares)			700,000

Stock-Based Compensation - Summ

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - 2006 and 2014 Stock Option Plans and Inducement Plan [Member] - Stock Options [Member] - USD ($) $ / shares in Units, $ in Thousands	9 Months Ended		12 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021
Share-Based Compensation
Number of Shares Outstanding, beginning of the period	197,171
Number of Shares, Granted	33,520
Number of Shares, Exercised	0	(1,566)
Number of Shares, Forfeited	(25,608)
Number of Shares, Cancelled	(11,863)
Number of Shares Outstanding, end of the period	193,220		197,171
Number of Shares, Exercisable	127,461
Number of Shares, Vested or expected to vest	182,864
Weighted-Average Exercise Price Per Share Outstanding, beginning of the period	$ 143.96
Weighted-Average Exercise Price Per Share, Granted	21.50
Weighted-Average Exercise Price Per Share, Forfeited	42.64
Weighted-Average Exercise Price Per Share, Cancelled	119.60
Weighted-Average Exercise Price Per Share Outstanding, end of the period	137.64		$ 143.96
Weighted-Average Exercise Price Per Share, Exercisable	186.38
Weighted-Average Exercise Price Per Share, Vested or expected to vest	$ 143.27
Weighted-Average Remaining Contractual Term, Outstanding	6 years 9 months 10 days		7 years 1 month 2 days
Weighted-Average Remaining Contractual Term, Exercisable	5 years 10 months 24 days
Weighted-Average Remaining Contractual Term, Vested or expected to vest	6 years 7 months 28 days
Aggregate Intrinsic Value, Outstanding			$ 51

Stock-Based Compensation - Sche

Stock-Based Compensation - Schedule of Estimated Assumptions Used to Calculate Weighted-Average Grant Date Fair Value of Options Granted (Detail) - Stock Options [Member] - 2006 and 2014 Stock Option Plans and Inducement Plan [Member]	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Share-Based Compensation
Weighted-average risk-free interest rate	2.27%	0.92%
Expected volatility	106%	104%
Expected terms	6 years	6 years

Stock-Based Compensation - Sc_2

Stock-Based Compensation - Schedule of Nonvested Restricted Stock Units Activity (Detail) - 2014 Stock Option Plan [Member] - Restricted Stock Units [Member]	9 Months Ended
	Sep. 30, 2022 $ / shares shares
Share-Based Compensation
Number of Shares, Nonvested restricted shares at the beginning of the period | shares	142,434
Number of Shares, Restricted shares granted | shares	160,575
Number of Shares, Restricted shares vested | shares	(50,352)
Number of Shares, Restricted shares forfeited | shares	(28,355)
Number of Shares, Nonvested restricted shares at the end of the period | shares	224,302
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the beginning of the period | $ / shares	$ 91.77
Weighted-Average Grant Date Fair Value, Granted | $ / shares	22.79
Weighted-Average Grant Date Fair Value, Vested | $ / shares	93.13
Weighted-Average Grant Date Fair Value, Forfeited | $ / shares	42.40
Weighted-Average Grant Date Fair Value, Nonvested restricted shares at the end of the period | $ / shares	$ 48.32

Stock-Based Compensation - Su_2

Stock-Based Compensation - Summary of Stock-Based Compensation Expense for Stock Options Granted that was Recorded in the Company's Results of Operations (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Stock-based compensation expense
Stock-based compensation expense	$ 1,354	$ 2,423	$ 5,440	$ 5,573
Cost of Product Revenue [Member]
Stock-based compensation expense
Stock-based compensation expense	64	40	309	211
Research and Development [Member]
Stock-based compensation expense
Stock-based compensation expense	230	269	851	707
Selling, General and Administrative [Member]
Stock-based compensation expense
Stock-based compensation expense	$ 1,060	$ 2,114	$ 4,280	$ 4,655

Warrants Associated with Term_2

Warrants Associated with Term Loan - Additional Information (Detail) - Common Stock [Member] - $ / shares	Dec. 31, 2019	Dec. 31, 2016
Class of Warrant or Right [Line Items]
Number of shares issuable for warrants outstanding	11,365	10,579
Exercise price of warrants	$ 77.50	$ 77.50

Net Loss Per Share - Additional

Net Loss Per Share - Additional Information (Detail) $ in Thousands	3 Months Ended	9 Months Ended
	Sep. 30, 2022 USD ($)	Sep. 30, 2022 USD ($) shares
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Net loss attributable to common stockholders | $	$ 330	$ 330
Stock split, conversion ratio		0.02
Reverse stock split description		the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.
Shares issued and outstanding immediately before the reverse stock split | shares		352,957,478
Shares outstanding immediately after the reverse stock split		7,059,144
Remaining shares issued | shares		345,898,334
Series A Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Net loss attributable to common stockholders | $		$ 300

Net Loss Per Share - Schedule o

Net Loss Per Share - Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	485,323	342,895	485,323	342,895
Options to Purchase Common Shares [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	193,220	186,352	193,220	186,352
Restricted Stock Units [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	224,302	134,599	224,302	134,599
Warrants to Purchase Common Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	64,801	21,944	64,801	21,944
Series A Redeemable Convertible Preferred Stock [Member]
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from the computation of diluted net loss per share	3,000		3,000

US Government Contract - Additi

US Government Contract - Additional Information (Detail) - USD ($)	1 Months Ended			3 Months Ended			9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2022	Mar. 31, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021	Dec. 31, 2021	Sep. 30, 2019
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				$ 3,677,000		$ 7,428,000	$ 16,822,000	$ 21,078,000
Contribution [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				1,036,000		3,122,000	7,778,000	8,444,000
Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Initial value of consideration receivable										$ 6,000,000
First contract option value exercised			$ 10,500,000
Option contract value exercised		$ 6,400,000
Collaborative arrangement additional funding amount received					$ 4,400,000
Collaborative arrangement additional funding amount to be received	$ 3,700,000
Accounts receivable	$ 0			0			0		$ 1,900,000
Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member] | Contribution [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue				$ 1,000,000		$ 3,100,000	$ 7,800,000	$ 8,400,000
Co Development Partnership Agreement [Member] | Biomedical Advanced Research and Development Authority [Member] | Maximum [Member]
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Aggregate consideration receivable										$ 69,000,000

Leases - Additional Information

Leases - Additional Information (Detail) - USD ($)		1 Months Ended							9 Months Ended
	Nov. 30, 2014	Sep. 30, 2022	Sep. 30, 2021	Oct. 31, 2020	Aug. 31, 2018	Sep. 30, 2017	Apr. 30, 2015	Nov. 30, 2014	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2019
Leases [Line Items]
Operating lease right-of-use assets		$ 9,058,000							$ 9,058,000	$ 9,766,000
License Agreement [Member] | Operating Lease Entered into November 2014 [Member] | Office Space [Member]
Leases [Line Items]
Lease expiration date						Dec. 31, 2021	Dec. 31, 2017
Security deposit	$ 50,000							$ 50,000
Lease termination date	Dec. 31, 2021
Office Space, Laboratory Space, and Equipment [Member]
Leases [Line Items]
Operating lease right-of-use assets		0							0
Lease liabilities		0							$ 0
Maximum lease period to not recognize right of use assets or lease liabilities									12 months
Office Laboratory And Manufacturing Space | Operating Leases Entered Into May2013
Leases [Line Items]
Operating lease right-of-use assets		200,000							$ 200,000
Lease liabilities		$ 200,000							200,000
Lease expiration date		Dec. 31, 2024		Dec. 31, 2022	Dec. 31, 2020
Laboratory Space [Member] | Operating Lease Entered into November 2014 [Member]
Leases [Line Items]
Lease expiration date				Oct. 31, 2025
Security deposit		$ 130,977							130,977		$ 281,000
Term of lease	6 years							6 years
Space build-out costs paid	$ 1,400,000							$ 1,400,000
Space build-out costs								$ 2,200,000
Security deposit received from landlord										$ 281,000
Office, Research, Laboratory and Manufacturing Space [Member] | Operating Leases Entered Into September 2021 [Member]
Leases [Line Items]
Operating lease right-of-use assets		0							0
Lease liabilities		0							0
Security deposit		$ 1,000,000							$ 1,000,000
Term of lease			126 months

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - License Agreement [Member] - USD ($)	9 Months Ended	24 Months Ended
	Sep. 30, 2022	Dec. 31, 2007	Sep. 30, 2021	Dec. 31, 2006
Commitments and Contingencies [Line Items]
Shares issued		1,693
Royalty on net sales sublicensing gross revenue	10%
Royalties accrued	$ 100,000		$ 100,000
Minimum [Member]
Commitments and Contingencies [Line Items]
Annual license fee payable				$ 5,000
Percentage of royalty on net sales	0.50%
Maximum [Member]
Commitments and Contingencies [Line Items]
Annual license fee payable				$ 25,000
Percentage of royalty on net sales	3.50%

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) $ in Millions

1 Months Ended

3 Months Ended

9 Months Ended

Oct. 12, 2022

Oct. 11, 2022 shares

Nov. 09, 2022 USD ($) shares

Sep. 30, 2022 shares

Jun. 30, 2022 shares

Mar. 31, 2022 shares

Jun. 30, 2021 shares

Sep. 30, 2022 shares

Oct. 26, 2022 USD ($) shares

Aug. 15, 2022 shares

Dec. 31, 2021 shares

Sep. 30, 2021 shares

Mar. 31, 2021 shares

Dec. 31, 2020 shares

Subsequent Event [Line Items]

Stock split, conversion ratio

0.02

Reverse stock split description

the changes in the number of shares resulting from the 50 to 1 reverse stock split that was approved by shareholders on October 11, 2022 and became effective as of October 12, 2022.

Stock issued during period, shares, stock splits

345,898,334

Common stock, shares issued

7,050,849

7,050,849

3,328,017

Common stock, shares outstanding

7,050,849

7,050,849

3,328,017

Temporary equity, shares issued

3,000

3,000

0

Common Stock [Member]

Subsequent Event [Line Items]

Issuance of common stock from secondary offering, net (in shares)

3,080,451

517,352

70,981

336,188

Common stock, shares issued

7,050,849

3,968,983

3,428,245

3,315,273

7,050,849

3,328,017

3,319,355

2,969,832

2,961,579

Subsequent Event [Member]

Subsequent Event [Line Items]

Stock split, conversion ratio

0.02

0.02

Reverse stock split description

On October 12, 2022, we effected a reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares. All common stock amounts and references have been retroactively adjusted for all figures presented to reflect this split unless specifically stated otherwise

On October 11, 2022, at the Company’s annual meeting of stockholders, the Company’s stockholders approved an amendment to the Company’s restated certificate of incorporation to effect a reverse stock split of the Company’s common stock. Following the receipt of the stockholders’ approval, the Company’s board of directors approved the reverse stock split at the ratio of 1 post-split share for every 50 pre-split shares, which was effective as of October 12, 2022. On October 31, 2022, the Company received a letter from Nasdaq informing the Company that it has regained compliance with the Bid Price Rule.

Subsequent Event [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Reverse stock split description

50 shares of issued and outstanding common stock of the Company were automatically reclassified and combined into 1 share of common stock

Stock issued during period, shares, stock splits

50

Common stock, shares issued

7,059,144

Common stock, shares outstanding

7,059,144

New Sales Agreement [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Issuance of common stock from secondary offering, net (in shares)

256,628

Proceeds from issuance of common stock | $

$ 0.7

Purchase Agreement [Member] | Series A Redeemable Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Temporary equity, shares issued

3,000

Purchase Agreement [Member] | Subsequent Event [Member] | Series A Redeemable Convertible Preferred Stock [Member]

Subsequent Event [Line Items]

Temporary equity, shares issued

3,000

Aggregate amount | $

$ 0.3